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The cell needs to exert a tight control over gene expression in order for the information 
to flow properly in time and space. To achieve this, the information stored in the 
genome must be highly organized for its correct deployment. There is increasing 
evidence that suggests that the three dimensional (3D) structure of the genome plays a 
major role in its organization and function. Different architectural proteins that bind 
chromatin are key players in 3D genome structure, and among these, CTCF has been 
described to have a major role in this process. In this work we aimed to explore the role 
of 3D genome structure mediated by CTCF in the developing heart. We find that Ctcf is 
essential for heart development, and that its loss gives rise to gross cardiac 
malformations that eventually lead to embryonic death. In order to gain a global view of 
the impact of Ctcf loss in the embryonic heart, we examined its genome-wide effects on 
the transcription. We observe that Ctcf is necessary to activate the cardiac 
developmental transcription program, and it does so by bringing together heart 
enhancers and target genes. We also assessed the role of CTCF as an insulator in 
several genomic contexts where binding sites for this factor are located between genes 
with divergent expression patterns, finding that CTCF does not always act as an 
insulator and that surely is not the only player responsible to separate distinct 
regulatory landscapes. 
We focused on the IrxA gene cluster that comprises Irx1, Irx2 and Irx4, as an example 
where to understand how 3D genome structure and the regulation of gene expression 
are mediated by CTCF. To do so, we performed chromosome conformation capture 
analysis by 4C-seq to interrogate the interaction domains established by the promoters 
of the genes from the cluster and how they changed upon CTCF deletion. We found 
that Ctcf loss disrupts the 3D genome structure of the cluster by markedly affecting the 
Irx4 interaction domain. This had an impact on gene expression of the members of the 
cluster and its neighboring genes. Irx4 was downregulated, and on the contrary Irx1, 
Irx2 and the first three telomeric genes from the cluster, Ndufs6, Mrlp36 and Lpcat1 
were upregulated. Based on the 4C-seq profile we found that the regulatory landscape 
of Irx4 is delimited by CTCF binding sites, where different cardiac enhancers are 
located. Finally, we also found that a specific CTCF binding site located between Irx2 
and Irx4 is necessary to establish the 3D genome structure of the Irx4 locus and for 
proper Irx4 gene expression. 
We show that the 3D structure mediated by the architectural protein CTCF is 
necessary for proper heart development. 
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La célula necesita ejercer un alto control sobre la expresión génica para que la 
información fluya adecuadamente en tiempo y en espacio. Para lograr esto, la 
información almacenada en el genoma debe estar altamente organizada para que se 
despliegue correctamente.  Cada vez hay más evidencia sugiriendo que la estructura 
tridimensional  (3D) del genoma juega un papel importante en su organización y 
función. Diferentes proteínas arquitecturales que se unen a la cromatina son 
elementos clave en la estructura 3D del genoma, entre estas proteínas CTCF tiene un 
papel importante en este proceso. Nuestro objetivo era explorar el papel de la 
estructura 3D mediada por CTCF en el desarrollo de corazón. Encontramos que Ctcf 
es esencial para el desarrollo cardiaco, y que su pérdida da lugar a malformaciones 
cardiacas que eventualmente conllevan a la muerte embrionaria. Para obtener una 
visión global del impacto de la pérdida de Ctcf en el corazón embrionario, examinamos 
los efectos en la transcripción de todo el genoma. Observamos que Ctcf es necesario 
para activar el programa transcripcional de desarrollo cardiaco, y lo consigue cuando 
une enhnacers de corazón y genes blanco. También evaluamos el papel de CTCF 
como aislador en varios contextos genómicos,  en los cuales sitios de unión de este 
factor están localizados entre genes con patrones de expresión divergente, 
encontramos que CTCF no siempre actúa como aislador y que seguramente no es el 
único elemento responsable de separar dominios regulatorios distintos. 
Nos enfocamos en el cluster  IrxA que contiene los genes Irx1, Irx2 y Irx4, como un 
ejemplo para entender como la estructura 3D del genoma y la regulación de la 
expresión génica son mediadas por CTCF. Para conseguir esto, realizamos un análisis 
de captura de la conformación del cromosoma, por 4C-seq, para interrogar los 
dominios de interacción establecidos por los promotores de los genes del cluster y 
como estos cambiaban al eliminar CTCF. Encontramos que la pérdida de Ctcf 
desestabiliza la estructura 3D del cluster, afectando marcadamente el dominio de 
interacción de Irx4. Esto tuvo un impacto en la expresión génica de los miembros del 
cluster y de sus miembros vecinos. Irx4 estaba downregulado, mientras que Irx1, Irx2 y 
los tres primeros genes teloméricos  del cluster, Ndufs6, Mrlp36 y Lpcat1 estaban 
upregulados. Basados en el perfil de 4C-seq, encontramos que el dominio regulatorio 
de Irx4 está delimitado por sitios de unión a CTCF, donde se localizan varios 
enhancers cardiacos. Finalmente, también encontramos que un sitio específico de 
unión a CTCF localizado entre Irx2 e Irx4 es necesario para establecer la estructura 
genómica 3D del locus de Irx4, así como para su expresión génica adecuada.  
Aquí mostramos que la estructura 3D mediada por la proteína arquitectural CTCF es 
necesaria para el desarrollo cardiaco adecuado. 
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A major challenge in developmental biology is to understand how a single cell gives 
rise to a complex multicellular organism. All the information necessary to achieve this 
lies in the genome, an organism´s complete set of DNA including all of its genes. It is 
clear that two kinds of information exist within the genome, and to understand this 
better we can divide the genome into coding and non-coding regions. The coding 
genome includes exons that ultimately translate into proteins. Remarkably, the exon-
coding region comprises only 2% of the genome (R. P. Alexander et al. 2010). The 
remaining 98% of the genome includes non-coding sequences that are required to 
control gene expression, eg when and where a gene must be expressed or silenced, 
and this establishment and maintenance of differential patterns of gene expression is 
key for proper spatial and temporal flow of information from the genome to the cell 
during development. 
In order to exert tight control over gene expression, information must be highly 
organized. To achieve this, the genome is packed into a compacted chromatin scaffold, 
and the basic unit is the nucleosome. It consists of DNA wrapped around a protein 
histone octamer. This configuration helps to package and organize the genome into the 
nucleus (van Steensel 2011). 
 
Fig. 1. The regulatory genome and its organization. 
The genome is organized in several levels. First, it associates with histone octamers to form the 
nucleosomes (light green circles). When these nucleosomes are tightly united they form the 
heterochromatin, a structure that impedes gene expression. The H3K9me3 histone modification 
is associated with heterochromatin. Nucleosome separation allows the recruitment of several 
proteins and constitutes the euchromatin. The H3K4me1 histone modification is associated with 
enhancers that recruit transcription factors to later activate transcription. The H3K27ac 
modification is present in active regions of the chromatin. Looping occurs to bring together 
regulatory elements with target promoters, or to group several genes that respond to the same 
regulatory elements. CTCF (blue circles) and cohesin (red ring) participate in looping 
stabilization. H3K27me3 associates with repressive chromatin domains. 
The functional properties of the genome depend on multiple levels of organization. 
Structurally, the chromatin is divided into gene-rich, less condensed euchromatin and 
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gene-poor, highly compacted heterochromatin, usually referred to as active and 
inactive chromatin, respectively (Solovei et al. 2016). An additional level of 
organization, the so-called epigenetic phenomenon, is based on modifications to the 
chromatin, such as methylation and acetylation of specific residues on specific 
histones, which serve to label regions of DNA as active, inactive, promoters, 
enhancers, among others. At the level of the primary nucleotide sequence, a myriad of 
binding sites exist for the diverse repertoire of transcription factors that help to establish 
tissue identity (Fig. 1). Beyond these well-characterized interactions, increasing 
evidence suggests that the three-dimensional (3D) genome structure, i.e. the 
conformation of the chromosomes, also plays a major role in organization and genome 
function (Bonora et al. 2014).  
1. Genomic regulatory elements 
The main goal of nuclear organization is to ensure proper gene expression. Genes that 
require to be expressed depend on different regulatory elements that are distributed 
along the genome. Some of the main types of regulatory elements are promoters, 
insulators, repressors and enhancers (Merkenschlager and Odom 2013; Symmons and 
Spitz 2013). A promoter is a region of DNA that initiates transcription of a given gene. 
An insulator is a region of DNA that, when placed between two genes, prevents the 
regulatory elements acting on one gene act over the second gene, and vice versa. 
Repressors inactivate transcription and are related to the recruitment of the Polycomb 
complexes, CpG islands or the association with the nuclear lamina (Blackledge et al. 
2015). An enhancer is operationally defined as a region of DNA that can activate 
transcription from a target promoter in an orientation- and location-independent manner 
(Smallwood and Ren 2013). Enhancers can be physically close to the gene, within the 
gene body, or can be located many hundreds of kilobases from the gene. 
Enhancers act as scaffolds where transcription factors bind to remotely control gene 
expression (Garcia-Gonzalez et al. 2016). Increasing evidence suggests that remote 
regulatory elements such as enhancers come into proximity with the target gene by 
looping, and that this looping can be protein-mediated (Sexton and Cavalli 2015). This 
looping is not random. There are examples where looping is necessary for proper gene 
expression (Ribeiro de Almeida et al. 2011), and others where looping seems to poise 
the genes before transcription (Ghavi-Helm et al. 2014). At the same time, genes also 
need to be shielded from other regulatory elements that could cause inadequate gene 
expression (Handoko et al. 2011). This proposed looping mechanism between 
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enhancers and target promoters is an example of how 3D structure influences gene 
expression (Fig2). 
 
 
Fig. 2. Enhancer promoter interactions. 
Regulatory elements, such as enhancers, can be several kilobases away from their target gene, 
like the depicted on the top panel. They come into close proximity via a looping mechanism to 
activate gene expression, like depicted on the bottom panel.  
2. The three-dimensional structure of the genome 
The three-dimensional (3D) genome structure refers to the spatial distribution of the 
chromatin in the nucleus, and evidence suggests that it is not random (Bickmore 2013; 
Cremer and Cremer 2001). Rather, it is organized to achieve the most efficient spatial 
distribution to guarantee proper gene regulation (Bickmore 2013). This is reflected in 
the nuclear architecture by the existence of structural and functional units, including 
chromosome territories, lamina-associated domains (LADs) (Bickmore 2013), and 
topologically associating domains (TADs) (Dixon et al. 2012).  
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A chromosome territory refers to the space that each chromosome occupies in the 
nucleus. However, it is not a fixed position. In some cells, the tendency is for gene-rich 
chromosomes to reside in the middle of the nucleus and for gene-poor chromosomes 
to reside in the nuclear periphery. In other cells, chromosomes are distributed 
according to their size; large chromosomes reside in the periphery and smaller ones lie 
inside the nucleus (Cremer and Cremer 2001).  
The nuclear lamina (NL) is a filamentous meshwork composed of lamin proteins 
located in the nucleus periphery (Kind and van Steensel 2010). Varying sizes (0.1–10 
Mb) of DNA associates with the NL, forming LADs. LADs usually contain gene-poor 
chromatin, and genes within LADs are generally transcriptionally silent (Kind and van 
Steensel 2010). However, genes associated with LADs dynamically change during 
development depending on whether they are turned on or off (Peric-Hupkes et al. 
2010). 
There are many interactions that occur simultaneously inside a chromosome. However, 
they occur more frequently in discrete domains that have an aproximate size of 1 
megabase, indicating that the chromosomes are compartmentalized (Dixon et al. 
2012). These discrete domains are the TADS. Interactions between TADs are much 
less frequent, and they are delimited by the TAD boundaries, which are enriched in 
CCCTC-binding factor (CTCF) sites, housekeeping genes, and interspersed repeats of 
the SINE family (Dixon et al. 2012). Inside the TADs occur interactions at lower scales, 
connecting regulatory elements with their target genes (Dixon et al. 2012; Nora et al. 
2013). Accordingly, the current view is that gene expression regulation occurs largely 
inside a delimited region of DNA (Dixon et al. 2012). 
The discovery of TADs was a breakthrough in the genomic architecture field because 
they shape the way we now understand the genome in 3D. For example, long-range 
interactions were known before the discovery of TADs; such was the case for Sonic 
hedgehog (Shh) in the mouse. The regulation of this gene was striking because an 
enhancer element necessary for proper Shh expression and function was located 
almost 900 kb distant from the gene (Anderson et al. 2014). This long-range interaction 
is still considered to be surprisingly long; however, it is now considered as an intra-TAD 
interaction. Another example is the HoxD gene cluster. It has different regulatory 
elements at both sides of the cluster. Each side, that spans almost 1 Mb, acts upon 
specific members of the cluster (Lonfat and Duboule 2015). This was better understood 
after the description of the TADs because each half of the cluster belongs to a different 
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TAD (Lonfat and Duboule 2015) and, as mentioned above, the interactions between 
TADs are less frequent. 
How the 3D structure is formed and maintained is still an open question. Although, 
several proteins are involved in maintaining the genomic 3D structure, the most 
relevant in mammals is CTCF (Ong and Corces 2014). 
3. The architectural protein CTCF as a genome organizer 
CTCF is an eleven zinc finger DNA-binding protein that was first identified as a 
transcriptional regulator of the c-myc oncogene (Lobanenkov et al. 1990). It is 
implicated in many processes related to gene regulation including transcription 
(Vostrov and Quitschke 1997; Vostrov et al. 2002), imprinting (Hark et al. 2000), barrier 
insulation (Bell et al. 1999), looping and long-range interactions (Handoko et al. 2011), 
and X chromosome inactivation (Chao et al. 2002). It is highly conserved among 
eukaryotes, but is not present in yeast, Caenorhabditis elegans or plants (Ong and 
Corces 2014).  
Tens of thousands of binding sites for CTCF are found scattered throughout the 
genome (H. Chen et al. 2012a). A systematic analysis of CTCF binding sites revealed 
that they can be ubiquitous or cell type-specific (H. Chen et al. 2012a). Several post-
translational modifications, such as phosphorylation and poly(ADP-ribosyl)ation 
(PARylation), can interfere with CTCF binding to chromatin. Moreover, several CTCF 
binding partners, such as the transcriptional regulator Kaiso and the transcription factor 
YY1, have been reported (Phillips and Corces 2009).  
Initial work using reporter assays with CTCF suggested that it acted as an insulator, by 
preventing the activation of a promoter by an enhancer when a CTFC binding site was 
placed between them (Yang and Corces 2012). Genome wide analysis of CTCF 
binding site locations suggested that this protein establishes domain boundaries in 
chromatin, separating heterochromatin from euchromatin (H. Chen et al. 2012a), or 
delimiting chromatin epigenetic states (Merkenschlager and Odom 2013). A study in 
mouse embryonic stem cells (mESCs) involving chromatin interaction analysis and 
paired end tagging (ChiA-PET) indicated that CTCF organizes the genome in domains 
where each region is enriched in a specific combination of histone modifications 
(Handoko et al. 2011). Following the discovery of TADs, it was understandable to find 
CTCF in the boundaries of TADs, either alone or in combination with other factors. 
Strikingly, only 15% of the binding sites were found inside the boundaries (Dixon et al. 
2012).  
INTRODUCTION 
 
38 
 
CTCF has been described as the master weaver of the genome (Phillips and Corces 
2009), and today it is known as an architectural chromatin-associated protein with a 
pivotal role in organizing the genome (Ong and Corces 2014) together with cohesin 
and mediator complexes (Bonora et al. 2014; Kagey et al. 2010; Phillips-Cremins et al. 
2013). Several other proteins have also been reported to participate in long-range 
interactions such as SATB1 (Yasui et al. 2002), among others, which could also be 
considered as architectural proteins. However, CTCF, cohesin and mediator are 
currently recognized as the main architectural proteins (Bonora et al. 2014).  
Cohesin is a ring-shaped complex that was initially described as mediating sister 
chromatid cohesion (Nasmyth and Haering 2009), but recently a role in long-range 
interaction has also been described (Lee and Iyer 2012). Similar to CTCF, cohesin 
binds genome-wide, and 89% of cohesin binding-sites are co-occupied by CTCF (Lee 
and Iyer 2012). Also, cohesin binding at certain CTCF binding sites is CTCF-
dependent. The most attractive explanation for the combination of these two proteins in 
mediating long-range interaction is that cohesin maintains the loop by holding together 
the two sections of DNA. Although many sites are co-occupied, there is still a great 
proportion of single CTCF or cohesin binding sites, indicating that they can act together 
and independently of each other. Indeed, some reports describe that cohesin can 
mediate long-range interaction in a CTCF-independent manner (Lee and Iyer 2012). 
On the other hand, mediator, a transcriptional coactivator, has recently been described 
to play a role with the help of cohesion in bringing together enhancers and promoters in 
ESCs (Bonora et al. 2014; Kagey et al. 2010; Phillips-Cremins et al. 2013). Further 
studies have demonstrated that while these three proteins are all able to mediate long-
range interactions, they do not work at the same time. The most common interacting 
partners are CTCF/cohesin or mediator/cohesin (Phillips-Cremins et al. 2013). Also, 
CTCF seems to mediate constitutive and larger interactions, up to 1 Mb (Phillips-
Cremins et al. 2013). Conversely, mediator seems to facilitate cell-specific interactions 
and mediator alone or together with cohesin facilitates looping of 300–600 kb (Phillips-
Cremins et al. 2013). 
In vitro, the consequences of the absence of cohesin or CTCF in the global 3D 
structure are different. The absence of both proteins decreases intra-TAD interactions, 
but only the absence of CTCF increases inter-TAD interactions (Zuin et al. 2014), 
suggesting that although CTCF alone does not form a TAD boundary, it is necessary to 
maintain it.  
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The most notable and recent discovery in CTCF biology is that the orientation of its 
non-palindromic motif is related to TAD formation and hence to boundary demarcation 
(Rao et al. 2014). Evidence suggests that divergent CTCF binding sites establish a 
TAD boundary (Gomez-Marin et al. 2015; Rao et al. 2014), and that convergent binding 
sites lie inside of the TADs (Rao et al. 2014). This, together with the fact that only 15% 
of the CTCF binding sites are in the TAD boundaries, strongly suggests that it is not the 
number of CTCF binding sites that demarcates a boundary, but rather the combination 
of the CTCF binding site and its orientation. Moreover, recent work has shown that 
intra-TAD CTCF orientation also affects looping and/or gene expression (de Wit et al. 
2015; Guo et al. 2015).  
There are several examples where CTCF helps to finely tune gene expression (Ong 
and Corces 2014; Yang and Corces 2012) by bringing together regulatory elements 
with target promoters. Such is the case of the protocadherins-alfa (PCDH-α) gene 
cluster in neurons, where CTCF mediates looping between distinct promoters at the 
PCDHA cluster and the distant enhancer HS5-1 (Hirayama et al. 2012). CTCF can also 
influence V(D)J recombination in B-cells by promoting distal over proximal Vk elements 
usage (Ribeiro de Almeida et al. 2011). Since gene expression is more dynamic than 
TAD structure (in time and space), it is understandable that the majority of CTCF 
binding sites lie inside TADs. 
The full knock-out of CTCF is embryonic lethal (Fedoriw et al. 2004; Heath et al. 2008; 
Moore et al. 2012; Wan et al. 2008). Furthermore, conditional deletion in several 
systems alters proper development of B-cells, T-cells, neurons and macrophages 
(Heath et al. 2008; Nikolic et al. 2014; Ribeiro de Almeida et al. 2009; Ribeiro de 
Almeida et al. 2011; Shih et al. 2012), leads to apoptosis in limbs and early nervous 
system (Soshnikova et al. 2010; Watson et al. 2014) and affects the cell cycle in T-cells 
(Heath et al. 2008). The role of this protein in heart development is currently 
unexplored. 
4. How to look at the genome in 3D? 
Historically, fluorescent in situ hybridization (FISH) was the method of choice used to 
gain insight into the 3D structure of chromatin. FISH consists of fluorescently labeling 
regions of DNA to visualize them under the microscope (Bickmore 2013). Different 
sizes of DNA can be labeled, from kilo base-ranged regions up to entire chromosomes. 
Also, DNA and sub-nuclear compartments can be labeled simultaneously (Ferrai et al. 
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2010). Labeling DNA and/or nuclear sub-compartments showed that the positioning of 
genes and chromosomes was not random.  
 
At the chromosome level, FISH showed that chromosomes in the interphase nuclei 
have a preferred position, the chromosomes territories. This position is not fixed and 
changes in a cell-specific manner (Bickmore 2013; Ferrai et al. 2010). At the gene 
level, active genes tend to be in the center of the nucleus and inactive genes tend to be 
in the periphery. Moreover, genes can be associated with nuclear sub-compartments 
and these associations are related to gene repression or activation, eg if genes are 
associated with the NL or RNAPolII, respectively. FISH was also used to visualize long-
range chromatin interactions between target genes and regulatory elements located 
distant from the gene. For example the Shh gene and the ZRS enhancer that are 
separated by ~900 kb, and the Hoxd13 gene and the global control region that are 
separated by 180 kb (Bickmore 2013). 
 
In 2002, Dekker and colleagues devised a new PCR-based method to detect physical 
interactions of chromatin, which was termed 3C, for chromosome conformation 
capture. This approach consists of chromatin crosslinking (with formaldehyde), 
restriction enzyme-mediated digestion, and finally ligation of the chromatin with low 
amounts of DNA ligase to favor intramolecular ligation events, allowing the capture by 
PCR of regions of the genome in close spatial proximity in vivo (Dekker et al. 2002). 
Basically, the 3C approach answers the question if the region A is interacting with the 
region B. 
 
With the advent of new technologies, the 3C approach was subsequently modified and 
coupled with microarrays, and later with massive sequencing (de Wit and de Laat 
2012). From the evolution of this method, new 3C-based approaches arose: 
circularized chromatin conformation (4C- on chip and later 4C-seq), chromatin 
conformation capture carbon copy (5C), chromatin immunoprecipitation coupled with 
chromatin conformation capture (ChIP-loop and ChiA-PET) and chromatin 
conformation capture coupled with next generation Sequencing (Hi-C). 4C-seq 
searches for all interacting regions that occur with a specific region of interest, whereas 
5C searches in an unbiased manner all interactions that occur inside a genomic region 
up to Mb sizes. Hi-C searches all interactions that occur genome-wide. ChiA-PET also 
searches all interactions that occur genome-wide, but it focus on those interactions 
related to a specific chromatin-bound protein (Risca and Greenleaf 2015) (Fig. 3).  
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The 3C-based methods give insight into the 3D structure inside the chromosome and 
to a lesser extent between chromosomes. FISH can also give insight into the 3D 
structure inside of the chromosome but at a lower resolution. FISH is visually 
compelling but generally limited to looking at the locations of a few specific targets in a 
few hundred cells. Both methodologies aim to explore the 3D structure to further 
understand how it translates into a phenotype, only at different scales and with different 
resolution. This is why FISH can complement 3C-based methods and vice versa 
(Bickmore 2013). In this work, we have made extensive use of the 4C-seq approach.  
 
5.  Circularized Chromatin Conformation Capture: 4C-seq 
The original 3C method is limited by the number of primer pairs designed, and only two 
sites can be interrogated at the same time. These disadvantages can be overcome 
with 4C-seq because the massive sequencing step allows the interrogation of all the 
interactions occurring with a specific region (the viewpoint) at once (de Wit and de Laat 
2012).  
Several works have proven that 4C-seq is a powerful method to gain insight into 
genome organization and function. For example, exploring the interaction profiles from 
housekeeping and cell-specific genes showed that each type of gene presents 
constitutive and cell-specific interactions, respectively (de Wit and de Laat 2012). 
Further work showed that inactive genomic regions in ESCs form few interactions. 
These inactive regions do form interactions in differentiated cells, such as murine 
embryonic fibroblasts (MEFs). This indicates that the inactive chromatin in ESCs is 
disorganized and that it becomes organized by forming interactions upon 
differentiation. Strikingly when a MEF is reprogrammed, the interactions of the inactive 
regions formed upon differentiation are lost (de Wit et al. 2013). It has also been shown 
that a genomic site that contains binding sites for several pluripotent factors tends to 
interact more with similar regions, i.e. those also containing pluripotency factor binding 
sites. A similar scenario occurs with Polycomb repressed regions (de Wit et al. 2013). 
In general, genomic regions tend to interact with other genomic regions with similar 
features. Furthermore, the sequential activation of the Hoxd cluster genes coincides 
with the sequential formation of interactions between the cluster genes and their 
regulatory elements (Noordermeer et al. 2011). Several works support the idea that 
enhancers can interact with promoters without activating their transcription, thereby 
gaining a poised regulatory architecture (de Wit and de Laat 2012; Ghavi-Helm et al. 
2014). Given that 4C-seq reveals, in an unbiased manner, all the interacting regions, it 
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can therefore be used to search previously unknown regulatory regions (van de 
Werken et al. 2012b), allowing a better understanding of the regulation of genes (van 
Weerd et al. 2014) and even explaining complex disease-related phenotypes (Smemo 
et al. 2014). 
 
Fig. 3. Overview of 3C-based methods. 
The 3C-based methods aim to capture interactions occurring in the crosslinked chromatin. What 
varies between methods is the number of genomic regions interrogated (3C and 4C focus on 
one region, 5C focuses on many and Hi-C interrogates the whole genome) and the size of the 
genomic region explored (3C explores only one region, 4C explores the whole genome, 5C 
explores up to 1Mb, and Hi-C explores the whole genome). The top panel depicts the steps 
common to all methods. The middle panels depict the variations for each method. The bottom 
panels illustrate a descriptive summary of each method. Taken from (de Wit and de Laat 2012). 
 
6. Testing the functional genome 
Studies on 3D structure have shown that physical interactions translate into 
phenotypes and that constant crosstalk occurs between coding and non-coding 
sequences, which is necessary for gene regulation. To further understand the 
relevance of the coding and non-coding sequences and how they work, several 
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strategies have been devised to address these issues, both in vitro and in vivo. Some 
of these are common to both types of sequences and others are sequence type-
specific. Coding sequences can be deleted, overexpressed and mutated. The function 
of non-coding sequences can be tested by the ability of a region of DNA to activate 
expression of a reporter gene, e.g. transient transgenic assays, or to repress 
expression. Non-coding sequences can also be deleted, mutated or inverted. Genetic 
manipulation of the DNA is required for these processes and can be time consuming, 
particularly if the goal is to test the non-coding sequence in vivo by generating 
transgenic organisms. The CRISPR/Cas9 technology has proven to be a powerful 
genome-editing tool because of its efficiency (Seruggia and Montoliu 2014). 
  
6.1 Genome editing by CRISPR/Cas9 
The CRISPR/Cas9 system has been used successfully in a wide variety of fields 
(Seruggia and Montoliu 2014). Despite its early discovery as a bacterial genome-
editing tool (Jinek et al. 2012), this technology has proven beneficial to get insight into 
mammalian genome organization and function. Regarding 3D structure, CRISPR/Cas9 
editing has been used to disrupt boundary elements that are required to establish 
functional chromatin domains at the Hox clusters (Narendra et al. 2015), and to prevent 
aberrant interactions that could lead to cancer (Flavahan et al. 2016). In C. elegans, 
boundary disruption showed that the partitioning of the X chromosome resembles the 
TADs in mammals (Crane et al. 2015). A seminal work with the CRIPSR/Cas9 
technology was the demonstration that a TAD disruption in vivo leads to pathogenic 
gene-enhancer interaction, which recapitulated limb malformations (Lupianez et al. 
2015). Given that CTCF binding polarity (binding site orientation) is related to TAD 
boundary formation and to intra-TAD interactions (Gomez-Marin et al. 2015; Rao et al. 
2014), CRISPR/Cas9 technology was used to invert CTCF binding sites. Strikingly, this 
inversion disrupted looping (de Wit et al. 2015) and altered enhancer-promoter 
interactions necessary for proper gene expression (Guo et al. 2015).  
7. Heart development 
In mammals, the heart is the first organ to form during embryogenesis. After 
gastrulation, the primitive streak arises in the bilaminar disc. Primitive streak cells 
migrate anteriorly to form the cardiac precursor at embryonic day (E) 6.5. Cardiac 
progenitors then spread towards the two sides of the midline to form the cardiac 
crescent, initiating myocardial differentiation at E7.5. Both sides of the cardiac crescent 
move towards the midline and fuse, giving rise to the primitive cardiac tube (E8.0) with 
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arterial and venous poles. The cardiac progenitors that give rise to the primitive cardiac 
tube are a cell population called the first heart field (FHF) that will contribute to the left 
ventricle, the atrioventricular canal and both atria (Buckingham et al. 2005). The 
resulting cardiac tube continues growing by the addition of pharyngeal mesoderm cells 
at both poles. This cell population is termed the second heart field (SHF), and will 
contribute to the outflow tract and all other heart regions except the left ventricle 
(Buckingham et al. 2005). Simultaneously, the heart tube undergoes rightward looping 
and subsequently divides into chambers, one common atrium and one common 
ventricle, connected by the atrioventricular canal. The venous and arterial pole of the 
heart can be distinguished as the cardiac inflow and outflow tract, respectively. At E9.5, 
cells coming from the proepicardium, an extracardiac cell population cover the 
myocardium to form the epicardium. The epicardial layer is involved in the formation of 
a subset of coronary endothelial cells, coronary smooth muscle cells, part of the AV 
valves, and cardiac fibroblasts (Luxan et al. 2016). By E10.5, two types of myocardium 
coexist: the proliferative compact myocardium and the trabecular myocardium. At this 
stage, cardiac septation begins to physically separate the heart chambers. In the 
atrioventricular canal and outflow tract, a transcriptional program that blocks 
myocardium identity is activated, allowing valve formation to occur. Trabecular 
remodeling begins after formation of the four chambers. At E12.5, cardiac neural crest 
cells invade the outflow tract and participate in the proper development of the outflow 
tract valves (Luxan et al. 2016). The heart is fully functional by E14.5, and supports 
systemic and pulmonary blood circulation through the aorta and pulmonary trunk, 
respectively (Buckingham et al. 2005) (Fig. 5).  
The cardiac transcriptional program has been extensively characterized (Bruneau 
2002). Consequently, many key genes involved in different aspects of heart 
development have been described, including Nkx2.5, Hand1, Mef2, Islet (Buckingham 
et al. 2005), Irx4, Tbx5 (Bruneau 2002), Notch (MacGrogan et al. 2010), Pitx2 (Franco 
and Campione 2003), Nppa (Bruneau 2002), Hopx (Trivedi et al. 2010), etc. Among 
these transcription factors, Nkx2.5 plays a key role in the differentiation and 
morphogenesis of the early developing heart (Bruneau 2002), and is expressed in the 
two distinct heart fields. For this reason, to assess the relevance of the absence or 
overexpression of a given gene using the Cre/LoxP system, Cre recombinase is 
typically driven by the Nkx2.5 promoter (Stanley et al. 2002).  
In addition to the study of genes directly related to heart morphogenesis and 
patterning, some works have addressed the relevance of epigenetics in heart 
development. These works have focused on several Polycomb members (J. M. 
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Alexander et al. 2015; Beketaev et al. 2015; L. Chen et al. 2012b) and chromatin 
remodeling factors (Lickert et al. 2004; Luna-Zurita and Bruneau 2013; Takeuchi et al. 
2011). The study of the three dimensional structure in heart development remains 
largely unexplored (van Weerd et al. 2014). 
 
Fig. 4. An overview of heart development. 
A. In the mouse, cardiac progenitor cells originate in the primitive streak (PS) at E6.5. B. At 
E7.5, these groups of cells migrate towards the two sides of the midline (ML) and form the 
cardiac crescent. C. At E8.0, both sides of the cardiac crescent will fuse in the midline and form 
the cardiac tube. D. At E8.5, the cardiac tube undergoes rightward looping and divides into 
chambers. E. At E10.5, the four chambers are defined but are not yet fully separated (upper 
panel is a frontal view, lower panel is a dorsal view). F. At E14.5, the four chambers are 
separated and the heart is fully functional. HFs = head folds; OFT = outflow tract; RV = right 
ventricle; LV = left ventricle; PRA = primitive right atrium; PLA = primitive left atrium; RA = right 
atrium; LA = left atrium; IFT = inflow tract; AVC = atrioventricular canal; SVC = superior vena 
cava; IVC = inferior vena cava; IVS = interventricular septum; Ao = aorta; AA =aortic arch; PT = 
pulmonary trunk; PV = pulmonary vein; Tr = trabeculae. Taken from (Buckingham et al. 2005). 
7.1. Iroquois genes 
The iroquois or Irx are a group of genes coding for homeodomain transcription factors 
with multiple roles in early development. Irx genes are expressed in the developing 
heart. Some members of this group have been shown to have roles in heart 
morphogenesis (Kim et al. 2012). 
 
Iroquois genes were first identified and described in Drosophila as playing a role in 
neural development (Gomez-Skarmeta and Modolell 2002). These genes were named 
after the Iroquois American Indian tribe because their absence in Drosophila produced 
flies without lateral bristles in the thorax, and this phenotype resembled the hair style of 
the American tribe (Cavodeassi et al. 2001).   
In Drosophila, there are three iroquois genes located in one cluster (Cavodeassi et al. 
2001). The molecular characterization of these genes in the fly allowed their 
subsequent identification in vertebrates. In mammals, six members of the Iroquois 
family were identified(Bosse et al. 1997; Houweling et al. 2001). Mapping analysis of 
the six iroquois genes revealed that they are distributed in two clusters (Cluster A and 
B). Each cluster, as in the fly, contains three genes. Cluster A comprises Irx1, Irx2 and 
A B C D E F 
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Irx4, and Cluster B comprises Irx3, Irx5 and Irx6. Strikingly, each cluster spans a large 
genomic region of ~1.5 Mb (Cluster A) and ~1 Mb (Cluster B). Since each cluster only 
harbors three members, the iroquois genes constitute a good example of what is called 
“gene deserts” (Gomez-Skarmeta and Modolell 2002). In the fly, the iroquois cluster 
also occupies a large genomic territory of 130 kb (Gomez-Skarmeta and Modolell 
2002). Sequence comparison between the six genes showed that each member of 
Cluster A has a paralogous gene in Cluster B (Irx1~Irx3, Irx2~Irx5, Irx4~Irx6), and it 
was suggested that the two clusters came from an ancestral duplication of a three 
member cluster (Peters et al. 2000). Moreover, the genomic organization of each 
cluster, which includes the sequential order of the genes inside the cluster, the 
orientation in which they are transcribed and the coding and non-coding sequences, is 
conserved in mammals (Gomez-Skarmeta and Modolell 2002) (Fig. 5).  
 
Fig. 5. Genomic organization of iroquois genes. 
Humans and mouse have six iroquois genes distributed in two clusters. Each cluster spans ~ 1 
Mb and contains only three genes each. Each gene from the cluster A has a paralogous 
member in the cluster B. Paralogous genes are depicted in the same colour, darker in the 
cluster A and lighter in the cluster B. The number of genes in each cluster, their location and 
distribution inside the cluster, together with the orientation of transcription, the coding 
sequences and the non-coding sequences constitute the genomic organization of these genes, 
and is conserved in mouse and humans. In the fly, there are only three iroquois genes and they 
also span a large territory (~130 kb). Furthermore, the orientation is not the same as in 
mammals for all the genes. Modified from (Gomez-Skarmeta and Modolell 2002). 
 
Initial studies of these genes in the mouse focused on their expression pattern. The 
aim was to determine whether they played a similar role as in Drosophila (Bosse et al. 
1997). These studies showed that the iroquois genes were expressed not only in the 
developing nervous system, but also in the limb, in the developing heart and in other 
territories (Bosse et al. 1997; Christoffels et al. 2000; Houweling et al. 2001).  
 
The expression patterns of Irx1, Irx2, Irx3 and Irx5 in the developing mouse are highly 
similar and their expression territories are wide (Houweling et al. 2001). By contrast, 
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Irx4 and Irx6 show a divergent and more restricted expression pattern (Houweling et al. 
2001). In the nervous system, Irx1, Irx2, Irx3 and Irx5 expressed in the median plane of 
the neural tube and the otic cap but at different levels. There are other nervous system 
territories where not all of the four genes are present, like the ganglion of the eight 
cranial nerve (Houweling et al. 2001). The non-overlapping expression patterns are 
better appreciated in limbs and in the developing heart. In the limbs at E10.5, Irx1 is 
expressed in the apical ectodermal ridge of the forelimb, Irx2 is expressed in all the 
limb bud and Irx3 presents a gradient expression in the proximodorsal margin of the 
limb (Bosse et al. 1997). In the developing heart, all six iroquois genes are expressed. 
From E9.5 to E12.5 Irx1/Irx2 expression is restricted to the interventricular septum, Irx4 
is broadly expressed in the ventricles, Irx3 expression is restricted to the trabecular 
myocardium, and Irx5/Irx6 are expressed in atrial and ventricular endocardium (Kim et 
al. 2012) (Fig. 6). 
 
A functional role for these genes in neural and cardiac development has been shown 
(Bao et al. 1999; Cavodeassi et al. 2001; Gaborit et al. 2012). In the context of this 
project, the developing heart, Irx3 and Irx5 regulate atrioventricular canal 
morphogenesis and outflow tract formation (Gaborit et al. 2012). Irx4, the member of 
the family with the broadest expression pattern in the heart, establishes ventricular 
identity (Bao et al. 1999). Irx1–5 are expressed in the adult heart and they have also 
been studied in this context. The expression territories of the iroquois genes expressed 
in the adult heart, with the exception of Irx3, are similar to those in the developing heart 
(Kim et al. 2012) (Fig. 6). In the adult heart, Irx3 participates in the ventricular 
conduction system (Zhang et al. 2011), Irx5 regulates the cardiac repolarization 
gradient (Costantini et al. 2005), and Irx4 is necessary to prevent abnormal ventricular 
gene expression that can later lead to cardiomyopathy (Bruneau et al. 2001).    
 
Given that the iroquois genes share expression territories, especially in the nervous 
system, it was hypothesized that these genes shared regulatory elements such as 
enhancers. A study carried out in Xenopus and zebrafish strongly supported this idea, 
since a functional screening of enhancers inside the non-coding regions of Cluster B 
showed that several enhancers were capable of driving expression in shared iroquois 
expression territories (de la Calle-Mustienes et al. 2005). A similar scenario was found 
for Cluster A (Tena et al. 2011). Also, since the genomic organization is conserved 
across species, it was hypothesized that their genomic organization was necessary for 
proper iroquois gene regulation possibly by sharing enhancers located inside 
conserved non-coding regions (Cavodeassi et al. 2001). Further work using 3C 
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Fig. 6. Iroquois gene expression in the heart. 
All six iroquois genes are expressed in the heart. The top panel shows the expression patterns 
in the early mouse developing heart. Irx1 and Irx2 are expressed both in the interventricular 
septum and in the near compact and trabecular myocardium. Irx3 is only expressed in the 
trabecular myocardium. Irx4 is highly expressed in ventricle myocardium. Irx5 and Irx6 are 
expressed in all the endocardium lining the atria and ventricles. The bottom panel shows the 
expression patterns from E14.5 to adult stage. Taken from (Kim et al. 2012) 
methodology (that tests the physical interaction between two regions of DNA) showed 
that indeed this was the case. In the Cluster A, there is physical interaction between 
enhancers and promoters and some enhancers are shared by more than one member 
of the Cluster. Also, the physical interaction between Irx1 and Irx2 promoters is 
conserved in vertebrates and is tissue independent, whereas the interactions between 
enhancers and promoters are tissue specific. CTCF is present in the promoters of the 
iroquois genes and downregulation of CTCF in zebrafish with morpholinos disrupted 
Irx1 and Irx2 promoter interaction. CTCF downregulation also dysregulated Cluster B 
gene expression. Thus, this conserved 3D structure seems to be CTCF dependent 
(Tena et al. 2011). Taking together, the iroquois genes seem to be an ideal system to 
study the relationship between 3D structure and gene expression. 
In this work we aimed to understand how the 3D genome architecture, mediated by 
CTCF, impacts gene expression in the developing mammalian heart. 
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All the information necessary for proper development and tissue homeostasis lies in 
the genome. Moreover, gene expression control is necessary for the adequate flow of 
the information in time and space. The 3D structure of the genome has a role in gene 
regulation, and the architectural proteins are key players involved in 3D structure. In 
vertebrates, CTCF is an essential architectural protein necessary for development, 
whose role in the heart development was unexplored. In this work we aimed to 
understand how the 3D genome architecture, mediated by CTCF, impacts gene 
expression in the developing mammalian heart. To achieve this goal, we defined the 
following objectives: 
• Analyze the impact of Ctcf deletion in the mammalian developing heart. 
 
• Determine whether 3D structure is altered either globally and/or locally upon 
Ctcf deletion, using 4C-seq. 
 
• Determine whether 3D structure mediated by CTCF controls gene expression. 
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1. Mouse strains                      
1.1. Breeding and genotyping 
We used the Cre/LoxP system to delete Ctcf in the embryonic heart by crossing two 
different mouse strains. A mouse line carrying the Cre recombinase construct under 
the control of the Nkx2.5 promoter, which is expressed in myocardium and 
endocardium (Stanley et al. 2002), was kindly provided by Dr José Luis de la Pompa 
(CNIC). The mouse line carrying the Ctcf floxed allele was generated in the laboratory 
of Niels Galjart (Erasmus MC, Rotterdam, The Netherlands) (Fig. 7) (Heath et al. 
2008). 
 
Fig. 7. Conditional targeting of the Ctcf gene. 
A diagram of the Ctcf gene showing the positions of its 12 exons is shown at the top. The DNA length 
scale is shown in kilobases (K). The resulting Ctcf deleted allele is shown at the bottom. Modified from 
(Heath et al. 2008). 
Nkx2.5-Cre; Ctcffl/+ males were crossed with Ctcffl/fl females, giving the following four 
possible genotypes:  
Ctcf fl/fl; Nkx2.5-Cre, referred to here also as Ctcf mutant or Ctcf KO. 
Ctcf fl/+; Nkx2.5-Cre, referred to here also as heterozygous 
Ctcf fl/fl, referred to here also as control 
Ctcf fl/+, referred to here also as control. 
MATERIALS AND METHODS
 
 
56 
 
Table 1. Genotyping primers for Ctcf and Nkx2.5-Cre alleles 
Primer Sequence Notes 
NKX2.5-Cre   GATGACTCTGGTCAGAGATACCTG Forward for Nkx2.5-Cre allele 
NKX-S      GCCCTGTCCCTCAGATTTCACACC Forward for Nkx2.5 wildtype allele 
Nkx-AS      GCGCACTCACTTTAATGGGAAGAG Reverse common primer for Nkx2.5 
p8563 CTAGGAGTGTAGTTCAGTGAGGCC Forward common primer for Ctcf 
p8946 GCTCTAAAGAAGGTTGTGAGTTC Reverse for Ctcf wildtype allele 
p261 CGGCATCAGAGCAGCCGATTG Reverse for Ctcf floxed allele 
p260 TGTCACTAATCTCCACCTCACAG Reverse for Ctcf deleted allele 
Primers for the Nkx2.5 allele were taken from (Stanley et al. 2002). Primers for the Ctcf allele 
were taken from (Heath et al. 2008) 
For genotyping, each transgene was tested independently. The Nkx2.5-Cre allele was 
detected by the presence/absence of a PCR product using three primers in the same 
reaction: a common reverse primer and two different forward primers. The wild-type 
allele PCR product was 200 base pairs (bp) and the Nkx2.5-Cre allele was 500 bp. Ctcf 
wild type, floxed, or deleted alleles were detected using three primers in the same 
reaction: a common forward primer and two different reverse primers. The Ctcf wildtype 
allele PCR product was 383 bp, the Ctcf floxed allele was 747 bp, and the Ctcf deleted 
allele was 750 bp. The primers used for this analysis are listed in Table 1 and the PCR 
conditions for each transgene are shown in Table 2. 
Table 2. PCR conditions for the Ctcf and Nkx2.5-Cre allele 
Ctcf alleles 
 
Initial Denaturation 95ºC 5 min 
Denaturation  94ºC 1 min 
Annealing 1  69ºC 1 min  35 cycles 
Annealing 2  60ºC 1 min 
Elongation  72ºC 1 min 
Final Elongation 72ºC 10 min 
Hold   4ºC ∞ 
 
Nkx2.5-Cre allele 
 
Initial Denaturation 94ºC 5 min 
Denaturation  94ºC 30 sec 
Annealing  60ºC 30 sec  30 cycles 
Elongation  72ºC 1 min 
Final Elongation 72ºC 10 min 
Hold   4ºC ∞ 
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1.2. Embryo collection 
Mouse embryos of different genotypes for different experimental procedures were 
collected at several stages, from E9.5 to E14.5. For transient transgenic experiments, 
embryos were collected from E9.5 to E13.5. 
2. Histology and tissue staining 
2.1. Embryo processing 
Embryos to be sectioned were dissected in cold phosphate buffered saline (PBS), fixed 
in 4% PFA overnight at 4°C, dehydrated through a graded ethanol series (30%, 50%, 
70%, 90% and 100%; 20 min each) and stored at −20°C until processing. Ethanol was 
diluted with RNAse-free water. Embryos were rehydrated by reversing the ethanol 
series and were processed for histological analysis of hematoxylin and eosin staining, 
RNA in situ hybridization on sections, or immunostaining. After rehydration, embryos 
were washed in xylene for 2×30 min, soaked in xylene:paraffin (1:1) for 30 min at 65ºC 
and then embedded in paraffin at 65ºC for 2×30 min. Before the paraffin became solid, 
the embryo inside the paraffin block was disposed vertically under a dissecting 
microscope to obtain transversal sections of the heart. Once the paraffin was solid, the 
blocks were stored at 4ºC until further processing. 
For RNA in situ hybridization of whole-mount embryos, embryos were dehydrated 
through a methanol series (50%, 75% and 100%; 20 min each) and embryos were 
stored at -20ºC. Methanol was diluted in PBT (PBS + 1%Triton X-100). 
2.2. Hematoxylin and Eosin staining 
Sections were incubated at 65ºC for 20 min, dewaxed with xylene for 2×10 min, and 
rehydrated into distilled water in a decreasing ethanol series (twice with 100%, 90%, 
70%, 50%, 30% and finally distilled water; 5 min each; the ethanol was diluted in 
distilled water). Sections were incubated with Harris Hematoxylin (Merck, reference 
1.00317.1000) for 10 min. Then, Hematoxylin was removed with rinsing water. 
Sections were treated with 1% acid alcohol (1% HCl diluted in 100% ethanol) for 2-5 
min. Sections were washed with rinsing water for 5 min. Sections were incubated in 
aqueous eosin (Merck, reference 1.00317.1000) for 10 min. Then, eosin was removed 
with rinsing water. Sections were dehydrated through an ethanol series followed by two 
washes with xylene and mounted with Dpx Mountant medium (Sigma 06522). 
2.3. RNA in situ hybridization on paraffin sections. 
RNA in situ hybridization was performed on 7-µm-thick sections following a previously 
described protocol (Jostarndt et al. 1994; Kanzler et al. 1998) with a few modifications. 
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On the day prior to in situ analysis, sections were incubated at 37ºC overnight. On the 
next day, they were incubated at 65ºC for 20 min, dewaxed with xylene for 2×10 min, 
and rehydrated into PBS in a decreasing ethanol series (twice with 100%, 90%, 70%, 
50%, 30% and finally PBS; 5 min each). Ethanol was diluted with RNAse-free water. 
Sections were re-fixed with 4% PFA for 20 min at room temperature (RT) and washed 
twice with PBS for 5 min. Then, they were incubated 10 min at 37ºC with proteinase K 
at 10 µg/mL and washed with PBS for 5 min. They were re-fixed with 4% PFA for 5 min 
at RT and washed with PBS for 5 min. Then, sections were treated with 0.7 N HCl for 
15 min at RT while agitating, and washed with PBS twice for 5 min, then were 
incubated in 0.25% acetic anhydride (acetic anhydride was diluted in 0.1 M 
triethanolamine at pH 8) for 10 min at RT while agitating, and washed with PBS for 5 
min. Sections were given a final wash with RNAse-free water for 5 min before pre-
hybridization (see appendix A) for 2 h at 65ºC. Probes were hybridized overnight at 
65ºC with pre-hybridization buffer. PBS used for these steps was sterile. The next day, 
sections were washed twice with post-hybridization buffer I at 65ºC and then twice with 
post-hybridization buffer II at 65ºC. Later, were washed with maleic buffer (MABT) 
three times for 5 min each. Then, were blocked for 2 h at RT with blocking solution and 
then incubated with an anti-DIG antibody 1:2000 (Roche, reference 11 093 274 910) 
overnight at 4ºC in a humidified chamber. The next day, sections were washed twice 
with MABT for 10 min while agitating at RT and then washed again with MABT three 
times for 1 hour while agitating at RT. Then, they were washed with AP-buffer three 
times for 10 min while agitating at RT and finally developed with BM-purple (Roche, 
reference 11442074001). After this, sections were washed with PBS twice for 5 min, 
re-fixed with 4% PFA and washed again with PBS twice for 5 min. They were 
dehydrated through an ethanol series followed by two washes with xylene and 
mounted with Dpx Mountant medium (Sigma 06522). 
2.4. RNA in situ hybridization in whole-mount embryos  
Whole mount in situ hybridization was performed as previously described (Wilkinson 
and Nieto 1993). Whole-mount embryos were rehydrated through a decreasing 
methanol series (75%, 50%, 10 min each) followed by treatment with 6% H2O2 for 1 h 
at RT in the dark. After washing with PBT three times for 10 min, embryos were treated 
with proteinase K (10 µg/mL) for 7 min (E9.5 embryos) or 12 min (E10.5 embryos) at 
RT and quickly rinsed with PBT twice and then washed with PBT for 5 min at RT. 
Embryos were re-fixed for 20 min at RT with 0.25% glutaraldehyde diluted in 4% PFA, 
followed by one quick rinse with PBT and a further two washes with PBT for 5 min at 
RT. Embryos were then washed with pre-hybridization buffer at 65ºC for 5 min and 
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incubated for 2 h with pre-hybridization buffer at 65ºC. Probes were hybridized 
overnight at 65ºC. On the next day, embryos were washed twice with post-hybridization 
buffer I at 65ºC and twice with post-hybridization buffer II at 65ºC. Later, embryos were 
rinsed with TBST and then washed three times for 10 min at RT. Embryos were 
incubated with blocking solution for 2 h at RT, followed by overnight incubation at 4ºC 
with anti-DIG antibody 1:2000. The next day, embryos were washed with TBST three 
times for 5 min, and then washed again with TBST five times for 1 h. Embryos were left 
overnight in TBST at 4ºC. The next day, embryos were washed three times with NTMT 
buffer (appendix A) for 10 min at RT and developed with BM-purple. After developing, 
embryos were washed twice with NTMT buffer and stored in 4%PFA at 4ºC. All 
treatments and incubations were done with agitation. 
Table 3. Primers used for PCR-generated probes 
Primer Sequence 
Tnni2_F ACGTGGCTGAAGAGGAGAAA 
Tnni2_R TATTGGAGCGAGGCCAAGTA 
Tnni3_F GAGACCTCCAAGGTCACCAG 
Tnni3_R TTAAACTTGCCACGGAGGTC 
Tnnt1_F TGCACTAAAAGACCGCATTG 
Tnnt1_R TGGGGGCACTTTATTTTGAG 
Tnnt3_F GAAACCAAGACCCAAACTTAC 
Tnnt3_R TTTATTCCTAGACCCCAGAAG 
Ndufs6_F GGTTTCGGGGTTCAAGTGT 
Ndufs6_R TGGTGGGAGCATCCTTTATT 
Hopx_F AGCAGACGCAGAAATGGTTT 
Hopx_R CCCCTGCCTGTTCTGTTATC 
Mrlp36_F GCCCGAAGTTGATTAAGGAC 
Mrlp36_R CAAGAGCTTTTTGGCTCAGG 
Fgf13_F TCGCTCATCCGGCAAAAGAG 
Fgf13_R GGTTCTGTTATAGAGCCCTCG 
SP6 promoter ATTTAGGTGACACTATAGAA 
T7 promoter GTAATACGACTCACTATAGGG 
F stands for forward primer and R stands for reverse primer 
2.5. Digoxygenin-labeled riboprobe synthesis for in situ 
hybridazation 
Riboprobes used for in situ hybridization were either generated by PCR and then 
transcribed, or directly transcribed from plasmids containing the requisite cDNA. In the 
former, total RNA from mouse embryos at different stages (depending on the gene of 
interest) was extracted using the RNeasy Mini kit (Qiagen, reference 74106) and cDNA 
was synthesized with the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, reference 4368814). Primers were designed at the 3´UTR of the gene of 
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interest. Sp6 and T7 promoter sequences were added at the 5´ end of the forward and 
reverse primer, respectively. The sense probe was transcribed with SP6 and the anti-
sense probe was transcribed with T7. For plasmid probes, plasmids were linearized 
and transcribed with the appropriate restriction enzyme. Digoxygenin-labeled riboprobe 
synthesis was performed according to the manufacturer’s protocol (Roche). Further 
details of the probes are shown in Tables 3 and 4. 
Table 4. Probes contained in plasmids 
Probe Restriction 
Enzyme 
RNA 
Polymerase 
Origin 
Irx1 XbaI T3 José Luis Gómez 
Skarmeta 
Irx2 BamHI T3 José Luis Gómez 
Skarmeta 
Irx4 NotI, SpeI T7 José Luis Gómez 
Skarmeta 
Irx3 HindIII T7 José Luis Gómez 
Skarmeta 
Irx5 XbaI T3 José Luis Gómez 
Skarmeta 
Irx6 EcoRI T7 José Luis Gómez 
Skarmeta 
Nkx2.5 XbaI T7 José Luis de la 
Pompa 
Tbx20 SacII, NcoI Sp6 José Luis de la 
Pompa 
Nppa BamHI T7 José Luis de la 
Pompa 
Pitix2 SacII T3 José Luis de la 
Pompa 
Tbx2 EcoRI T3 José Luis de la 
Pompa 
Tbx3 PstI T3 Robert Kelly 
Tbx4 XbaI Sp6 María A. Ros 
Tbx5 EcoRV T7 José Luis de la 
Pompa 
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2.6. Immunohistochemistry 
For CTCF detection, slides were dewaxed and rehydrated, washed in distilled water 
and subjected to heat-induced epitope retrieval in citrate buffer. Briefly, 10 mM citric 
acid pH 6.0 was microwave heated for 3 min, then slides were microwave heated for 
15 min and left to cool to RT for 15 min. Slides were then washed with distilled water 
and endogenous peroxidase was blocked for 30 min with 3% H2O2 (diluted in 
methanol). Sections were washed with PBST (PBS + 0.1% Tween-20) and blocked for 
1 h in 10% goat serum in PBS. Slides were incubated for 1 h at RT with rabbit 
polyclonal anti-CTCF antibody (1:500) (Soshnikova et al. 2010). Then, slides were 
washed with PBST twice for 5 min and incubated for 30 min at RT with a biotinylated 
secondary antibody goat anti-rabbit (1:300 diluted in PBST). Slides were washed with 
PBST twice for 5 min and incubated for 30 min at RT with Vectastain Elite ABC Kit 
(reference vector VC-PK-6100-KI01), washed three times for 5 min with PBST and 
developed with the Peroxidase Substrate Kit for DAB (reference Vector SK-4100). 
Slides were washed with distilled water, dehydrated through an increasing ethanol 
series (70%, 95%, 100% 2 min each), cleaned with xylene (twice for 5 min) and 
mounted in Dpx Mountant medium (Sigma 06522). 
2.7. Phosphohistone 3 (PH3) and TUNEL staining 
PH3 and TUNEL staining was performed in 5-µm-thick sections. The protocol is 
designed to perform both staining on the same samples at once. The protocol starts 
with the TUNEL, then is followed by PH3 staining and ends up with the incubation of 
secondary antibodies for each staining at the same time. Slides were incubated 
overnight at 37ºC and then incubated at 65ºC and dewaxed with xylene twice for 5 min. 
They were hydrated three times with 100% ethanol, once with 95% ethanol, and once 
with water, 5 min each. Then, they were rinsed with distilled water three times and 
antigens were retrieved with 10 mM citric acid pH 6.0 as before. Slides were then 
washed with distilled water and endogenous peroxidase was blocked for 40 min with 
1% H2O2 (diluted in methanol) in the dark. They were then rinsed quickly with distilled 
water three times and washed once with distilled water for 5 min. Incubation with 0.5% 
Triton X-100 diluted in PBS for 10 min at RT was followed by a PBS rinse three times 
and then a PBS wash for 5 min. From this step onwards, slides were incubated in a 
humidified chamber in the dark. They were incubated with 1mM CoCl2 in TdT buffer for 
15 min at RT followed by incubation with TdT mix (appendix A) for 1 hour at 37ºC. 
Then, slides were washed with 1mM CoCl2 in TdT buffer for 10 min. The reaction was 
stopped by washing in 0.01% Tween 20 diluted in PBS twice for 5 min. This was 
followed by three 5 min washes in PBS. Next part is the PH3 staining. Slides were 
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blocked with Histoblock for 1 hour at RT, followed by incubation with an anti-PH3 
antibody (1:200, Millipore, reference 06-570) for 1 hour at 37ºC. They were washed 
three times with PBS for 5 min. This is the final part for both stainings. Incubation with 
secondary antibody Alexa488 goat anti-rabbit (1:500, Molecular Probes, reference 
A11034) and streptavidin-Cy3 (1:500 Jackson, reference 016-160-084) for one hour at 
RT, was followed by three washes with PBS for 5 min. Slides were incubated for 10 
min at RT with 4',6-diamidino-2-phenylindole (Dapi, Millipore 1246530100), washed 
three times with PBS for 5 min and finally mounted in Dpx Mountant medium. 
Quantification of TUNEL and PH3 staining were made with ImageJ software. Positive 
cells for each antibody were counted in 3–5 sections per heart. Three wild-type and 
three KO hearts were used. Statiscal significance was determined using one-tailed 
Student´s test from GraphPad. 
2.8. Imaging 
Hematoxylin and eosin staining, RNA in situ hybridization in sections, TUNEL and PH3-
immunostained slides were observed with an Olympus BX51 microscope and 
photographed with an Olympus DP71 digital camera and CellSens Entry Software. 
Whole-mount embryos processed for whole-mount RNA in situ hybridization and β-
galactosidase staining were observed using a Leica MZ FLIII Scope and photographed 
with a Nikon digital camera DMX 1200F and NIS-Elements D 3.2 software. Whole-
mount embryos fixed to photograph the Ctcf KO phenotype in Fig. 11 and Fig. 12 were 
observed with a Leica MZ FLIII Scope and photographed with an Olympus DP71 digital 
camera and NIS-Elements D 3.2 software. 
3. RNA-seq and data analysis 
3.1. Sequencing and analysis 
RNA-seq was performed on three pools of six E10.5 hearts each from control (Ctcffl/+), 
heterozygotes (Ctcffl/+; Nkx2.5-cre) and homozygous mutants (Ctcffl/fl; Nkx2.5-cre). 
Individual hearts were frozen in liquid nitrogen and stored at -80ºC. The yolk sac of 
each embryo was used for posterior genotyping. RNA was extracted with the 
miRNeasy Mini Kit (Qiagen, reference 217004). 
Sequencing was performed at the CNIC Genomics Unit using the GAIIx sequencer 
using a 75 bp single end elongation protocol.  Reads were aligned with Bowtie aligner 
(v0.12.7) using the transcriptome set from Mouse Genome Reference NCBIM37 and 
Ensembl Gene Build version 65. Then, they were quantified RSEM v1.20. Genes with 
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less than one count per million in more than three out of nine samples were filtered out. 
Thus, 14011 genes were considered for the differential expression analysis. Data were 
then normalized using a correction factor implemented in the bioconductor package 
EdgeR and described by Robinson & Oshlack (Robinson and Oshlack 2010). Finally, 
genes with an adjusted p-value <=0.05 were considered as differentially expressed.  
The matrix of normalized expression values was used to compute a Euclidian distance 
between samples and represented using heat map function. The heatmap (Fig. 8) 
shows that the control and the heterozygotes are in close proximity, indicating that they 
are similar. 
 
Fig. 8. Heat map with the samples and replicates used in the RNAseq. 
This representation shows that the control and the heterozygotes are more similar to each other 
and more different from the Ctcf KO. het = heterozygote. 
3.2. CTCF binding sites and heart enhancer analysis 
Distances between transcriptional start sites (TSS) of the DEGs (from the CTCF KO 
versus control comparison) and CTCF binding sites or predicted heart enhancers were 
analyzed using R statistical software. Coordinates for 8-week-old and E14.5 hearts 
CTCF binding sites and predicted heart enhancers were obtained from the Ren 
Laboratory at UCSD (http://chromosome.sdsc.edu/mouse/download.html) (Shen et al. 
2012)). For the analysis to determine if the TSS of the DEG genes were closer to a 
CTCF binding site or a predicted heart enhancer we used the Mann-Whitney test, that 
it is used for non-parametrics and independent datasets. For the analysis to determine 
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if the TSS of the DEG were closer to a CTCF binding site or a predicted heart enhancer 
in the 10 and 20 Kb windows, we used the Proportion test. 
3.3. Gene density analysis 
Gene density analysis was done using R statistical software. Distances between the 
transcriptional start sites (TSS) of the DEGs (from the Ctcf KO versus control 
comparison) and the first neighboring gene to both sides was measured in Kb. These 
two distances were added, and the sum of that was considered the total distance for 
each gene. Then, the median of the total distance was compared between upregulated 
and downregulated genes. To analyze if the difference between medians was 
significant, we used the Wilcoxon test, for non-parametric dependent datasets. The 
Density curves show the distribution of downregulated and upregulated genes in 
mutant hearts in relation to the distance from the TSS of adjacent 5’ and 3’ genes.  
3.4. Heat maps 
Heat maps to represent RNAseq differential expression several genes in Fig. 19 and 
28 were generated using heatmap.2 package function from G plots from the R 
package. 
3.5. Gene ontology 
Gene ontology (GO) enrichment analysis was performed using DAVID 
(http://david.abcc.ncifcrf.gov) with cut-offs of 10 genes and EASE value of 0.001. The 
EASE value is a modified Fisher Exact P-Value, for gene-enrichment analysis. The GO 
terms presented in this work are those included in the group 5 of biological process. In 
table 5 are the details for each column. The GO terms are ordered from high- to low-
fold enrichment. Further details from the GO term tables are shown in Table 5. 
Table 5. Gene Ontology columns description.  
Term Count % P-value Fold enrichment 
Enriched GO 
term 
associated 
with our gene 
list. 
Genes involved 
in the term. We 
established that 
each GO term 
should have at 
least 10 genes. 
Percentage of 
involved genes 
in the GO 
term. 100% is 
the total genes 
from the list. 
Modified Fisher 
Exact P-value, 
EASE Score. 
The smaller the 
score, the more 
enriched. 
Defined as the ratio of two 
proportions. The proportion of 
genes from our list enriched in 
a particular GO term, divided 
by the proportion of genes from 
the background enriched in the 
same particular GO term. 
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4. Mouse transgenic assays 
4.1 Cloning 
Mouse DNA fragments 1-7 (#1 chr13:73,307,200-73,308,500; #2 chr13:73,312,500-
73,318,000; #3 chr13:73,400,238-73,401,992; #4 chr13:73,414,400-73,416,300; #5 
chr13:73,418,664-73,422,000; #6 chr13:73,427,100-73,428,900; #7 chr13:73,435,722-
73,438,701; Mouse Genome Reference NCBIM37, mm9) were amplified by PCR 
(primers used are detailed in Table 6 and PCR conditions are detailed in Table 7) from 
genomic DNA of CD1 adult mice. PCR products were cloned in the pGEMTeasy vector 
(Promega, reference A1360). Fragments were then isolated from pGEMTeasy by NotI 
digestion and subcloned into the NotI site of the p1230 vector (Fig. 9). The tested DNA 
fragments together with the β-globin-LacZ  
 
Fig. 9. Map of the p1230 vector. 
The p1230 vector contains a human β-globin minimal promoter, the E. coli β-galactosidase (LacZ) gene 
and a SV40 polyadenylation signal, depicted in black, blue and grey, respectively. Unique cloning sites are 
shown in bold.  
cassette and SV40pA were released from the vector with SalI and SacII. Only fragment 
#2 was released with SalI and BgmBI, because this fragment had a SacII restriction 
site in its sequence (BgmBI is not present in the p1230 multicloning site). After release, 
fragment 2 looses 11 bp. Digested DNA was run in 1% low gelling temperature 
agarose (Sigma, reference A9414), and the fragment of interest was extracted with the 
QIAquick Gel Extraction Kit (Qiagen, reference 28704) and re-suspended in oocyte 
water (Sigma-Aldrich, reference W1503-100ML).  
Table 6. Primers for amplification of genomic fragments for transgenic assays 
Primer Sequence 
frag1_F CCTGCATTGCTCTGCTGTTTAA 
frag1_R TGGTCAGAAGGCAAATCTGAAGG 
frag2_F CCAGTCAGGCAATGTCTGTGTC 
frag2_R ACCATGTTAGGAGAGTGTTTCC 
frag3_F GCCAGACGGAGCAGTGGCATG 
frag3_R TGGTCAGAAGGCAAATCTGAAGG 
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frag4_F GGATAGCCAAACGGCCAGGC 
frag4_R GTGCTCTTAACTGCTGAGCCAT 
frag5_F GGTCCCACTCTAAAGCCCAGAA 
frag5_R GGAGGTCATGAAGAGATTGAATC 
frag6_F GACCAGCCTGGAACTCACAAC 
frag6_R GATGACTGAGTGGCACTCTGC 
frag7_F CCATTTCTAGAGAAGGCTGGTT 
frag7_R ACCAAGGTTGTCTCTGTGGG 
F stands for forward primer and R stands for reverse primer 
Table 7. PCR conditions for amplification of genomic fragments for transgenic 
assays 
 
Initial Denaturation 95ºC 5 min 
Denaturation  94ºC 30 sec 
Annealing  59ºC 30 sec  35 cycles 
Elongation  72ºC 2 min 
Final Elongation 72ºC 10 min 
Hold   4ºC ∞ 
 
 
4.2. Microinjection and embryo transfer 
Transgenic mouse embryos were generated as previously described (Aguirre et al. 
2015; Nagy et al. 2003). DNA was injected into the pronucleus of E0.5 B6/CBA mice at 
4–6 ng/µL diluted in microinjection buffer (appendix A). Embryos were then transferred 
to CD1 pseudo-pregnant females. Embryos were collected from E9.5 to E12.5, fixed 
and stained for β-galactosidase activity. Negative embryos for β-galactosidase activity 
were genotyped for LacZ and myogenin as an internal control by PCR to calculate 
transgenic efficiency. Primer details for LacZ and myogenin are shown in Table 8 and 
PCR conditions are shown in Table 9. 
Table 8. Primers for Transgenic Mouse Embryos 
Primer Sequence Notes 
lacZ_F GCGACTTCCAGTTCAACATC genotyping of transgenic embryos 
lacZ_R GATGAGTTTGGACAAACCAC genotyping of transgenic embryos 
Myogenin_F CCAAGTTGGTGTCAAAAGCC control for transgenic genotyping 
Myogenin_R CTCTCTGCTTTAAGGAGTCAG control for transgenic genotyping 
F stands for forward primer and R stands for reverse primer 
4.3. β-galactosidase staining 
Embryos were fixed with LacZ fix (37% formaldehyde, 2 mM MgCl2, 5 mM EGTA 
(Ethylene-bis(oxyethylenenitrilo)tetraacetic acid, glycol ether diamine tetraacetic acid, 
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reference Acids E3889), 0.2% glutaraldehyde) for 20 min at RT, washed with PBS + 
0.2% Tween for 20 min at RT and stained overnight with LacZ stain: 5 mM K3Fe, 5 mM 
K4Fe, 2 mM MgCl2, 1.04 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside, Sigma reference B4252).  
Table 9. PCR conditions for amplification of LacZ and myogenin. 
 
Initial Denaturation 95ºC 5 min 
Denaturation  94ºC 1 min 
Annealing  60ºC 1 min  30 cycles 
Elongation  72ºC 1 min 
Final Elongation 72ºC 10 min 
Hold   4ºC ∞ 
 
 
5. Circularized Chromosome Conformation Capture: 4C 
5.1. Tissue collection and fixation 
Pools of 45-65 hearts from controls or mutants were lysed and 4C was performed as 
previously described (Splinter et al. 2012; van de Werken et al. 2012a). Hearts were 
dissected from control (Ctcffl/+ or Ctcffl/fl) and mutant (Ctcffl/fl; Nkx2.5-cre) E11.5 
embryos. This stage was used in order to obtain enough starting material. Each heart 
was incubated with 48 U/µL of collagenase type II (Worthington, reference 4176) at 
37ºC for 45 min, minced with a p200 pipette tip and passed through a 70 µm cell 
strainer. Then, samples were centrifuged for 1 min at 2600 rpm and the supernatant 
was discarded. Samples were re-suspended with 600 µL of PBS and an equal volume 
of 4% PFA was added. Samples were then crosslinked for 10 min at RT with 2% PFA 
while agitating. Then 171 µL of cold glycine (final concentration 0.285 mM) was added 
and mixed by inversion. Samples were centrifuged for 8 min at 1300 rpm and 4ºC, the 
supernatant was discarded and samples were frozen with liquid nitrogen and stored at 
-80º for later processing once genotypes were established.  
5.2. Cell lysis 
Pools of hearts were re-suspended in 5 mL of cold 4C buffer with douncing on ice to 
increase lysis efficiency. Three microliters of disaggregated hearts were mixed with 3 
µL of Methyl Green-Pyronin stain (Sigma, reference HT70116) on a slide, which was 
overlayed with a coverslip to check cell lysis. Under the microscope, cytoplasm stains 
pink and nuclei stains blue/green. Once cell lysis was completed, samples were 
centrifuged for 5 min at 1800 rpm at 4ºC and supernatants were discarded. 
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5.3. First digestion 
Samples were re-suspended in 450 µL of MiliQ water with the addition of 60 µL of 10× 
DpnII restriction enzyme buffer (New England Biolabs, reference R0543M). Tubes 
were placed at 37ºC and 15 µL of 10% SDS was added followed by incubation at 37ºC 
and 900 rpm in the Ependdorf Thermomixer for 1 h. Next, 75 µL of Triton X-100 was 
added and incubation was continued as before for 1 h. From here, 5 µL of sample was 
removed as an undigested control. Then, 400 U of DpnII was added and samples were 
incubated as before overnight. On the next day, 200 U of DpnII was added and 
samples were incubated for a further 4 h. From here, 5 µL was removed as the first 
digestion control. To determine digestion efficiency, 92.5 µL of 10 mM Tris-HCl pH7.5 
was added to the 5 µL undigested and first digestion controls followed by addition of 
2.5 µL of proteinase K (20 mg/mL), and incubation for 1 h at 65ºC. Then, 1 volume 
(100 µL) of phenol-chloroform was added, tubes were vigorously shaken and 
centrifuged at 13000 rpm for 5 min at RT. The aqueous phase was recovered and 20 
µL was loaded onto a 0.6% agarose gel to visualize different sizes of DNA, “a smear” 
generated after digestion. 
5.4. First Ligation 
When the first digestion was completed, DpnII was heat inactivated at 65ºC for 20 min. 
A ligation reaction was set up in a final volume of 1500 µL (150 µL of 10× ligase buffer, 
60 U of T4 DNA ligase (Promega, reference 10481220001), ~500 µL of first digestion 
and water to 1500 µL) and incubated overnight at 4ºC. The next day, 50-100 µL was 
taken as first ligation control, to which 2.5 µL of proteinase K (20 mg/mL) was added 
followed by incubation for 1 h at 65ºC. Then, 1 volume of phenol-chloroform (50 or 100 
µL) was added, tubes were vigorously shaken and centrifuged at 16400 g for 10 min at 
RT. The control samples were then loaded onto a 0.6% agarose gel to visualize the 
shift in DNA size “smear” as a result of the ligation. 
5.5. Reverse crosslinking and DNA purification 
When the first ligation was completed, 15 µL of proteinase K (20 mg/mL) was added 
and samples were incubated overnight at 65ºC to reverse crosslinking. The next day 
30 µL of RNAse (10 mg/mL) was added and samples were incubated for 45 min at 
37ºC. The 1500 µL sample was then transferred to a 15 mL falcon tube and 1 volume 
of phenol-chloroform was added and samples were vigorously shaken. Following 
centrifugation at 3270g for 15 min at RT, the aqueous phase was transferred to a new 
15 mL falcon tube. Then, 1/10 volume of 3 M NaAC pH 5.6 (150 µL), 2.5 volumes of 
100% ethanol (3750 µL) and 20 µL of glycogen (Roche, reference 10901393001) were 
added, mixed by inversion and the mix was distributed into 1500 µL Eppendorf tubes, 
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which were incubated at -80ºC until samples were frozen (2-3 h). Samples were 
centrifuged at 10,000 rpm for 20 min at 4ºC, pellets were washed with cold 70% 
ethanol, centrifuged again as before, air dried, and dissolved in 150 µL of 10 mM Tris-
HCl pH 7.5 ~15 min at 37ºC and left overnight at 4ºC. 
5.6. Second Digestion 
To the 150 µL of the first digestion samples, 50 µL of 10× Csp6I buffer (Fermentas, 
reference ER0211), 50 U of Csp6I and MiliQ water up to 500 µL were added. Samples 
were incubated overnight at 37ºC and then 5 µL was removed as the second digestion 
control. Then, 95 µL of 10 mM Tris-HCl pH7.5 was added and 20 µL of all controls 
were loaded in a 0.6% agarose gel. 
 
Fig. 10. 4C seq. 
The left panel shows the graphical summary of the 4Cseq procedure. The right panel shows the 
logic for primer design: on the top, the primers face outward from the viewpoint and are 
depicted in red. The orientation is outward to perform inverse PCR. In the bottom of the right 
panel, the gray overhangs in the reading and non-reading primers represents the Illumina 
adaptors. Scheme was modified from (Splinter et al. 2012). 
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5.7. Second ligation and DNA purification 
When the second digestion was completed, Csp6I was heat-inactivated at 65ºC for 25 
min. A ligation reaction was set up in a final volume of 1500 µL (150 µL of 10× ligase 
buffer, 100 U of T4 DNA ligase, ~500 µL of second digestion and water to 1500 µL) 
and incubated overnight at 4ºC. The next day, 50-100 µL was removed as the second 
ligation control, and 20 µL of all controls were loaded in a 0.6% agarose gel; in total, 5 
control samples were loaded in a 0.6% agarose gel to visualize the shift in DNA 
spread. DNA was purified as for the second digestion. The pellet was re-suspended in 
50 µL of 10 mM Tris-HCl pH 7.5. Samples were purified with the QIAquick PCR 
purification kit (Qiagen, reference 28104). 
5.8. Primers and viewpoints   
Irx1, Irx2 and Irx4 primers were designed in the laboratory of Jose Luis Gómez 
Skarmeta, (CABD at Seville, Spain). Other primers were designed using the mouse 
mm9 version of the UCSC Genome Browser. The viewpoint is the DNA sequence 
between two restriction sites from the first enzyme, in our case DpnII. The ideal size is 
500 bp. The DNA sequence between the first and the second (Csp6I in our case) 
restriction enzyme should be at least 300 bp to allow circularization (van de Werken et 
al. 2012a). The reading primer is designed on top of the first restriction enzyme site 
with a 20 nt length. The non-reading primer design is more flexible and can be 100 bp 
from the second restriction enzyme site and with a length between 18 and 25 nt. Once 
designed, short primers were tested with decreasing DNA concentrations (100, 50, 25 
and 12.5 ng). Once checked, Illumina adaptors were added to the 5´end of the short 
primers so the PCR product is ready to sequence. P5 and P7 adapters are used for the 
reading and non-reading primer respectively (Splinter et al. 2012; van de Werken et al. 
2012a).  
5.9. PCR conditions  
For all experiments, 100 to 200 ng of the resulting 4C template was used for PCR with 
the Expand Long Template Polymerase (Roche, reference 11759060001) (primers 
used are detailed in Table 10 and PCR conditions are in Table 11). A graphical 
summary of the 4C-seq is in Fig. 10. 
Table 10. 4C viewpoint primers 
Primer Sequence 
Irx1_DpnII TCTCTGCTCTGGGTTGGATC 
Irx1_Csp6 TTGGGGCTCTCTGTCAAAC 
Irx2_DpnII GATGAGGGGTGCCCGATC 
Irx2_Csp6 CTGGGCATCCCACTTCTACA 
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Irx4_DpnII TCCGGCGCAAGAGCGATC 
Irx4_Csp6 GTAAGCGGATGGGAAGGAC 
Ndufs6_DpnII AGCATGTGTTGTTTGGGATC 
Ndufs6_Csp6 AACACTGCGCACAGTTAAGC 
CTCF BS_DpnII TGGAACCCACAGTGCTGATC 
CTCF BS_Csp6 ACCAGCAAATTAATCTACAAGGC 
Frag1_DpnII ATGTAATGTTGCTGGAGATC 
Frag1_Csp6 GCACTTAGGATGTGTTGACCC 
Adaptor reading primer AATGATACGGCGACCACCGAACACTC 
TTTCCCTACACGACGCTCTTCCGATCT 
Adaptor non reading 
primer 
CAAGCAGAAGACGGCATACGA 
The reading primers have DpnII and non-reading primers have Csp61 restriction sites 
Table 11. PCR conditions for 4C-seq library amplification 
 
Initial Denaturation 94ºC 2 min 
Denaturation  94ºC 10 sec 
Annealing  55ºC 1 min  30 cycles 
Elongation  68ºC 3 min 
Final Elongation 68ºC 5 min 
Hold   1º2ºC ∞ 
 
 
5.10. Sequencing and data analysis  
Sequencing was performed at the CNIC Genomics Unit using the GAIIx Illumina and 
the HiSeq 2000 Sequencer. Then raw sequencing data was de-multiplexed using the 
reading primer as barcode to identify the reads (captures) of each viewpoint. Reads 
were aligned to an in silico library generated based on the restriction enzymes used 
(Noordermeer et al. 2011; Splinter et al. 2012; van de Werken et al. 2012a), in our case 
DpnII and Csp6I. The mouse mm9 reference genome was used for the in silico library. 
For sample comparison between controls and mutants, the 4C data were normalized 
by total weight in a window of 15 Mb surrounding the IrxA cluster. The mean and 
standard deviation for each fragment were calculated for each group of replicates and 
the difference was determined between the means in control and mutants for each 
viewpoint. To assess whether these differences were statistically significant, the entire 
region was divided into sliding windows of 50 DpnII-Csp6I restriction fragments with an 
80% overlap and the number of reads in each window for each sample was counted. 
Data were compared using the R package edgeR (Robinson et al. 2010), which applies 
statistical tests based on negative binomial distributions. 
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6. Genome editing with the CRISPR/Cas9 system 
6.1. Guide RNAs 
Guide RNAs were designed with an online tool (http://crispr.mit.edu/). Details of the 
oligonucleotides are shown in Table 12. The T7 promoter sequence was added at the 
5´ end of each oligo and they were transcribed with the mMESSAGE mMACHINE® T7 
Ultra Kit Synthesis of Translation Enhanced Capped Transcripts (Thermofisher, 
reference AM1345).  
Table 12. Oligos for guide RNAs 
Oligos Sequence Location 
g5.3 GGCGTCCAATTGACAAATTG / PAM: TGG chr13:73297211-73297230 
g5.4 AATTTGAGTTCTCTCCGAAC / PAM: AGG chr13:73297805-73297825 
g3 CTTGTCCGTGCGGTCCAAC  / PAM: TGG chr13:73298566-73298585 
 
6.2. Microinjection, embryo transfer, collection and processing  
Two different combinations of guide RNAs (g5.4-g3 and g5.3-g3) together with a Cas9 
protein with a nuclear localization signal (PNA Bio reference CP01) were injected into 
the pronucleus of E0.5 B6/CBA F1 embryos. Guide RNAs were injected at 20–30 ng 
µL, and the Cas9 protein was injected at 6–72 ng/µL. Embryos were then transferred to 
CD1 pseudo-pregnant females, collected at E9.5-10.5 and processed individually for in 
situ hybridization and genotyping. Primers for genotyping and PCR conditions are 
described in Table 13 and 14, respectively. The PCR strategy was designed to 
distinguish the unaltered and the deleted allele by PCR product size. The unaltered 
allele was 1608 bp. The g5.3 and g3 combination produced a 1374 bp deletion and the 
PCR product size of the deleted allele using this guide RNA combination was 234 bp. 
The g5.4 and g3 combination produced a 779 bp deletion and the PCR product size of 
the deleted allele using this guide RNA combination was 829 bp. The size of the PCR 
products of two deletions, can vary since the deletion, although highly consistent was 
not exactly the same in each embryo. The PCR products of deleted alleles were cloned 
into a pGEMTeasy vector, and further sequenced to confirm that the desired deletion 
took place. 
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Table 13. Primers for deletion using the CRISPR/Cas9 system 
Primer Sequence 
CTCFdel_F AGGCCTTTAGCAGGAACCTC 
CTCFdel_R CGATCCTGGAACAGGAAAAA 
F stands for forward primer and R stands for reverse primer 
Table 14.  PCR conditions for amplification of the CTCF binding site deletion. 
 
Initial Denaturation 95ºC   5 min 
Denaturation  94ºC   1 min 
Annealing  58,6ºC   1 min      35 cycles 
Elongation  72ºC   1min,50sec 
Final Elongation 72ºC   10min 
Hold   4ºC   ∞ 
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1. Analysis of the Ctcf KO mouse embryonic heart phenotype 
1.1. Ctcf deletion in the heart results in embryonic lethality  
To investigate the role of CTCF during heart development, we used Cre recombinase 
driven by the cardiac homeobox gene promoter Nkx2.5 (Nkx2.5-Cre) to delete Ctcf in 
the embryonic mouse heart. This driver is functional as early as E7.5, when cardiac 
specification takes place (Stanley et al. 2002), and is expressed in the myocardium and 
endocardium leading to deletion in both myocardial and endocardial cells. From the 
crosses established to delete Ctcf in the heart, four possible genotypes are predicted. 
Animals homozygous for the Ctcf heart deletion (Ctcffl/fl;Nkx2.5-Cre, referred to in this 
work as Ctcf KO), heterozygous animals, which had only one Ctcf allele deleted 
(Ctcffl/+;Nkx2.5-Cre), and controls that were either homozygous or heterozygous for the 
Ctcf floxed allele (Ctcffl/fl or Ctcffl/+, respectively). Controls did not carry the Nkx2.5-Cre 
allele (Fig.11A appendix B). In theory, we expected to obtain 25% of each genotype. 
After weaning, we genotyped the litters and we failed to recover any Ctcf heart-specific 
KO (Ctcffl/fl;Nkx2.5-Cre), what was indicative of embryonic or perinatal lethality. Also, 
that one Ctcf allele is enough for proper heart development. To establish if embryo 
death was occurring, we collected embryos at different developmental stages. We 
recovered live Ctcf KO embryos up to E12.5 (Fig. 11A), whereas E13.5 embryos were 
dead (Fig. 11B,C). Furthermore, E13.5 embryos were not fully developed and were 
smaller in size than controls (Fig. 11B,C). We therefore conclude that deletion of Ctcf in 
the heart leads to embryonic lethality at E13.5.  
RESULTS 
 
78 
 
 
Fig. 11. Ctcf deletion in the heart is embryonic lethal. 
A, Graph showing the percentage of embryos obtained of each genotype. B, C, At 13.5, the 
heart Ctcf KO embryo is dead, delayed in development and smaller than the control. Scale bar 
is 500 µm. 
1.2. Ctcf deletion in the heart leads to cardiac malformations 
We next examined the general morphology of the Ctcf KO embryos and hearts at 
stages prior to death. The external appearance of the whole embryo at E11.5 was 
similar to that of the control (Fig. 12A,B), and this was also the case at earlier stages. 
When we examined E12.5 embryos, morphological differences were detected in the 
whole embryo, including pericardial edema (Fig. 12E-H). 
We removed the pericardium of these embryos to visualize the heart. The E11.5 Ctcf 
KO heart presented a reduction in size (Fig. 12C,D), which was exacerbated at E12.5 
(Fig. 12I,J). Embryos at these stages were alive, but presented heart malformations 
that very likely contributed to the lethality.  
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Fig. 12. Ctcf deletion in the heart alters heart development. 
A, Control embryo at E11.5. B, Ctcf KO embryo has no obvious morphological defects. C,D, 
The Ctcf KO E11.5 heart is reduced in size. E, Control embryo at E12.5. F, E12.5 thorax of 
control embryo. G, Ctcf KO embryo at E12.5. H, The Ctcf KO thorax shows a reduction in the 
size of the heart. I,J, The Ctcf KO E12.5 heart is smaller than the control. Scale bar in A, E and 
F is 500 µm. Sale bar in C and I is 200 µm. RA: right atrium, RV: right ventricle, OFT: outflow 
tract, LA: left atrium, LV: left ventricle. 
To examine the morphology in more detail, we performed hematoxylin and eosin (H&E) 
staining and CTCF immunostaining on E11.5 and E12.5 embryos. When KO embryos 
were compared with the control embryos, H&E staining of Ctcf KO embryos at E11.5 
revealed gross cardiac malformations that included a shorter and broader 
interventricular septum (IVS) (Fig. 13A,B) and a thinner compact myocardium (Fig. 
13C,D). CTCF immunostaining at E11.5 (Fig. 13E,F) showed that CTCF was absent in 
the Nkx2.5 territories (Fig. 13G,H arrows) but was present in territories where Nkx2.5 
was not expressed (Fig. 13G,H arrowheads pointing to the body wall) (Stanley et al. 
2002), confirming cardiac deletion of Ctcf in KO embryos. At E12.5, H&E staining also 
highlighted exacerbated gross cardiac malformations and the reduction in heart size 
was conspicuous (Fig. 14A-D). CTCF immunostaining at E12.5 demonstrated 
downregulation of the protein (Fig. 14E-H). 
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Fig. 13. Ctcf deletion in the heart causes gross cardiac malformations at E11.5. 
A-D, H&E staining in transverse sections of control and Ctcf KO E11.5 hearts. Ctcf KO shows a 
deformed IVS (arrowheads in A and B) and a thinner myocardium (bracket in C and D). E-H, 
CTCF immunostaining shows reduced CTCF expression in the KO heart (E,F). This 
downregulation is better appreciated in G and H. Arrows show Nkx2.5 territories and 
arrowheads show non-Nkx2.5 territories, the pericardium. RA: right atrium, RV: right ventricle, 
IVS: interventricular septum, AVC: atrioventricular canal, LA: left atrium, LV: left ventricle. Scale 
bars are 200 µm.   
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Fig. 14. Ctcf deletion in the heart causes severe cardiac malformations at E12.5. 
A,B, H&E staining in transverse sections of control and Ctcf KO E12.5 hearts. Ctcf KO showed 
severe morphological defects. C,D, Closer view of the left ventricles of control and Ctcf KO 
hearts, respectively.  E,F, CTCF immunostaining showed reduced CTCF expression in the Ctcf 
KO heart. This downregulation is better appreciated in G and H. Arrows show Nkx2.5 territories 
and arrowheads show non-Nkx2.5 territories, and point to the pericardium. Scale bars are 200 
µm. RA: right atrium, RV: right ventricle, IVS: interventricular septum, AVC: atrioventricular 
canal, LA: left atrium, LV: left ventricle.  
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1.3. Cardiac Ctcf deletion does not alter apoptosis or cell 
proliferation 
Previous studies in which Ctcf was deleted have shown that this deletion in some 
cases upregulates apoptosis (Hirayama et al. 2012; Soshnikova et al. 2010) and in 
others impedes cell proliferation (Heath et al. 2008; Ribeiro de Almeida et al. 2011). 
We therefore questioned whether these processes were altered in our model. To 
address this, we examined apoptosis by quantifying the number of TUNEL-positive 
nuclei, and we measured cell proliferation by quantifying PH3-positive nuclei in the 
whole heart. We chose to do this at E10.5 because this stage was the middle point 
between the onset of the conditional deletion (E7.5) and embryonic death (E13.5). 
Moreover, at this stage we could already detect CTCF downregulation (appendix E) 
and no overt morphological abnormalities. Immunostaining showed no apparent 
differences in the number of TUNEL-positive cells or PH3-positive nuclei between Ctcf 
KO and control hearts (Fig. 15 A,B, and D,E, respectively). These observations were 
corroborated by quantifying the number of cells, which were not different between the 
two samples. (Fig. 15 C,F). These results show that deletion of Ctcf in the heart does 
not alter apoptosis or cell proliferation at E10.5, although we cannot rule out that these 
processes are affected at later stages. 
 
Fig. 15. Ctcf deletion in the heart does not alter apoptosis or proliferation. 
A-C, TUNEL assays at E10.5 in control (A) and Ctcf KO hearts (B) revealed no differences 
between them (C). D-F, PH3 immunostaining in E10.5 control (D) and Ctcf KO hearts (E) also 
showed no difference between them (F), Scale bar is 200 µm. RA: right atrium, RV: right 
ventricle, LA: left atrium, LV: left ventricle, AVC: atrioventricular canal. 
2. Ctcf is necessary for the correct expression of cardiac genes 
To obtain a broader insight into the impact of deleting Ctcf in the developing heart, we 
decided to evaluate its effect on gene transcription. Thus, we performed RNA 
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sequencing (RNAseq) in embryonic hearts of the following genotypes: i) Ctcf KO 
(Ctcffl/fl;Nkx2.5-Cre), ii) controls (Ctcffl/+), and iii) heterozygous (Ctcffl/+;Nkx2.5-Cre) at 
E10.5, because of the reasons pointed above. After filtering the read counts of all 
samples and replicates, 14011 genes were considered as being expressed for further 
analysis. Principal component analysis (PCA) showed that samples for each condition 
grouped together and separately from the other conditions, indicating low variability 
within each condition and sufficient information to be differentiated between them (Fig. 
16). We then made three comparisons: i) Ctcf KO versus control, ii) Ctcf KO versus 
heterozygotes, and iii) heterozygotes versus control. Genes were considered to be 
differentially expressed at an adjusted p-value <=0.05, and were sorted by the absolute 
log2 Fold Change (Appendix C). 
 
Fig. 16. Principal Component Analysis (PCA) of the RNAseq samples. 
Graph shows how replicates of each sample group together, and how each sample group is 
separate from the other samples. 
In the comparison Ctcf KO versus control, we obtained 2335 differentially expressed 
genes (DEG) from a total of 14011 genes considered in the analysis (Fig. 17A). Of 
these, 1126 were upregulated and1209 were downregulated. In the comparison Ctcf 
KO versus heterozygotes, we obtained 1989 DEG, from these 1022 were upregulated 
and 967 were downregulated (Fig. 17B). Finally, in the heterozygous versus control, we 
obtained only 24 DEG, 15 upregulated and 9 downregulated (Fig. 17C), indicating that 
both samples were very similar. After this, we compared the DEG from Ctcf versus 
control against the DEG from Ctcf KO versus heterozygous and found 1422 genes in 
common, representing 60 and 71% of each group of DEG respectively. These results 
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indicate that one copy of Ctcf is sufficient for proper transcription at E10.5, and at least 
in the heart, Ctcf does not act in a dosage dependent manner.  
 
Fig. 17. RNAseq summary. 
Pie charts showing the three comparisons of gene expression in embryonic hearts analyzed by 
RNAseq for Ctcf KO versus control (A), Ctcf KO versus heterozygous (B), and heterozygous 
versus control (C). The upregulated and the downregulated genes are depicted in yellow and 
blue, respectively. The numbers inside the circles denote the precise number of genes of each 
category in each comparison. n indicates the total number of genes differentially expressed in 
each comparison. het: heterozygous, up-reg: upregulated, down-reg: downregulated. 
As a first approach to study the function of the DEG, we performed Gene Ontology 
(GO) analysis for Biological Processes terms using the DAVID functional annotation 
tool (https://david.ncifcrf.gov). In the comparison Ctcf KO versus control, we found 
enrichment of GO terms related to metabolism (such as tetrapyrrole biosynthetic 
process, cellular response to oxidative stress and cell cycle checkpoint, among others), 
and development (such as heart morphogenesis and heart development) (Fig. 18A and 
Table 16 appendix D). Subsequently, we divided DEG (of this comparison) into genes 
that were upregulated or downregulated in the mutant hearts compared to controls, and 
repeated the GO analysis with each group. Each data set was enriched for different 
GO terms. The GO terms related to heart development and function were present only 
in the downregulated dataset (Fig. 18B and Table 17 appendix D). Genes related to 
general developmental pathways such as NOTCH, BMPs, TGFbeta ERBb, and also 
several cardiac transcription factors were only present in the downregulated dataset 
(Fig. 19). Unlike the downregulated genes, the upregulated genes were enriched for 
GO terms related to general metabolism (Fig. 18C and Table 18 appendix D). GO 
analysis of the DEG from the Ctcf KO versus heterozygous showed a similar behavior 
as the Ctcf KO versus control. GO terms related to heart development and 
morphogenesis were present in all DEG and in the downregulated dataset (Tables 19-
22 appendix D). 
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Fig. 18. Gene Ontology analysis for the Ctcf KO versus control comparison. 
 
Each panel shows the top 15 GO terms in each data set, all DEG (A), downregulated genes 
(B), and upregulated genes (C). The GO terms are ordered from high- to low-fold change 
enrichment. 
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From all the DEG present in the Ctcf KO versus control comparison, we selected 
several cardiac transcription factors, such as Nkx2.5, Hopx, Tbx20, and Pitx2, also the 
cardiac chamber specific gene Nppa to evaluate their expression by in situ 
hybridization. Confirming the RNAseq data from the Ctcf KO versus control, we 
observed in some cases a general downregulation in gene expression, meaning that 
the downregulation was observed in the gene expression domain, in Ctcf KO hearts, 
for example Nkx2.5 (Fig. 10A), Hopx (Fig. 10B) and Tbx20 (Fig.10C). Moreover, other 
genes showed reduced expression in specific territories, for example Nppa, which was 
absent in the anterior ventricular trabeculae (asterisks in Fig. 20D), and Pitx2 in the 
right ventricle of KO hearts (arrows in Fig. 20E). In situ hybridization also confirmed 
strong upregulation of Fgf13 upon Ctcf deletion (Fig. 20F), a fibroblast growth factor 
homolog that is suggested to contribute to heart disease (Wei et al. 2011), and this was 
among the most highly upregulated genes in the Ctcf KO as compared to the control.  
 
 
Fig. 19. Ctcf deletion alters cardiac developmental pathways. 
Heat map showing the tendency of genes related to heart development (transcription factors 
and general developmental pathways such as BMP, NOTCH, EGF/ErbB and TGFbeta) to be 
downregulated in the in Ctcf KO hearts compared with controls. 
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3. Ctcf facilitates enhancer-promoter interactions in the 
embryonic heart 
Previous studies have shown that there are several thousand Ctcf binding sites 
distributed genome-wide (H. Chen et al. 2012a; Shen et al. 2012). We examined the 
relationship between the DEG in the Ctcf KO versus control comparison and the 
presence of CTCF binding sites in their vicinity. To do this, we used the public available 
data (Shen et al. 2012) for CTCF Chip-seq in E14.5 and 8-week-old mouse hearts.  
 
Fig. 20. Ctcf deletion alters heart developmental gene expression. 
In situ hybridization shows that Ctcf deletion alters gene expression in the developing heart. It 
can cause general downregulation, as is the case for Nkx2.5 (A), Hopx (B), or Tbx20 (C); or 
downregulation in specific domains of expression, for example Nppa (D, asterisks show anterior 
ventricular trabeculae), Pitx2 (E, arrows point to the right ventricle). Fgf13 (F), is a fibroblast 
growth factor that is upregulated in Ctcf KO. RA: right atrium, RV: right ventricle, IVS: 
interventricular septum, AVC: atrioventricular canal, LA: left atrium, LV: left ventricle. Scale bar 
is 200 μm. 
Furthermore, since we previously observed that upregulated and downregulated genes 
were enriched in different GO terms (Fig. 18), we decided to also evaluate them 
separately in this analysis. We used the genes present in the RNAseq that were not 
unchanged in the Ctcf KO versus control comparison (appendix C) as the background 
for the comparisons. Thus, in each dataset, we mapped the Transcription Start Site 
(TSS) of each gene, and used this position as a fixed reference point. We then utilized 
the available public data (Shen et al. 2012) to assess the distance from the TSS of 
each DEG to its closest CTCF binding site. We then compared these distances for the 
downregulated or upregulated genes versus those for the expressed but unchanged 
genes. We found that the upregulated and downregulated genes were closer to a 
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CTCF binding site than genes whose expression did not change upon Ctcf deletion 
(Fig. 21A). Next, we questioned the relationship between the same elements (TSS of 
the DEG and the CTCF binding sites) when examined in a delimited genomic window 
of 10 or 20 kb surrounding the TSS. We assessed the DEG separately (upregulated 
and downregulated versus expressed but unchanged in the Ctcf KO versus control 
comparison) and queried the number of DEG that had a CTCF binding site inside the 
delimited genomic window. We found that both, downregulated and upregulated genes 
presented a significantly higher proportion of genes that had a CTCF binding site within 
10 or 20 kb genomic windows when compared with the expressed but unchanged 
genes in the Ctcf KO versus control comparison (Fig 21B). 
 
Fig. 21. Distance from the DEG from Ctcf KO versus control comparison to the nearest 
CTCF binding site. 
A, Differentially expressed genes (DEG) in the Ctcf versus control comparison, either 
upregulated (blue) or downregulated (pink), lie closer to a CTCF binding site than the expressed 
but unchanged genes (green). **, p<0.0005; Mann-Whitney test for DEGs vs expressed P = 
2.475797e-13. B, This tendency is also appreciated in genomic windows of 10 and 20 kb. *, 
p<0.01; Proportions test. P values are listed as follows: in the 10 Kb window, down-reg versus 
expressed P = 1.54E-16, and up-reg versus expressed P = 0.000000121; in the 20 Kb window, 
down-reg versus expressed P = 1.42E-08, and up-reg versus expressed P = 1.79E-09. 
Shen and colleagues (2012) used the chromatin histone modification H3K4me1 
together with p300 promoter-distal binding sites to train an enhancer prediction tool, 
and predict heart enhancers for E14.5 and 8-week adult stages (Shen et al. 2012). We 
used these predicted heart enhancers to examine the relationship between them and 
the DEG in the Ctcf KO heart versus the control. Again, we evaluated this separately in 
the downregulated and upregulated genes. As in the analysis of the relationship 
between CTCF binding sites and DEG (Fig. 21A), we mapped the TSS of each gene 
and used this position as a fixed reference point. We assessed the distance from each 
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DEG to its closest predicted heart enhancer, and then compared these distances from 
the downregulated or upregulated genes versus those for the expressed but 
unchanged genes in the Ctcf KO versus control comparison. We found that both 
datasets were significantly closer to a predicted heart enhancer than genes whose 
expression did not change upon Ctcf deletion (Fig. 22A). After this, we questioned the 
relationship between the same elements (TSS of the DEG and the predicted 
enhancers) when examined in a delimited genomic window of 10 and 20 kb. We 
assessed the DEG separately (upregulated and downregulated versus expressed but 
unchanged in the Ctcf KO versus control comparison) and queried the number of DEG 
that had a predicted heart enhancer inside the delimited genomic windows. We found 
that only the downregulated genes presented a significantly higher proportion of genes 
that had a predicted heart enhancer within 10 or 20 kb genomic windows, when 
compared with the control (Fig 22B). Although DEG genes are closer to a heart 
enhancer, the distance between the upregulated genes to a heart enhancer is similar to 
the expressed but unchanged genes. Thus, when we restricted the genomic windows 
to 10 and 20 kb, only downregulated genes are significantly closer to a heart enhancer. 
 
Fig. 22. Distance from the DEG from Ctcf KO versus control comparison to the nearest 
heart enhancer. 
A, Genes downregulated (pink) and upregulated (blue) in the Ctcf KO versus control 
comparison lie closer to a previously described heart enhancer than unchanged (green) genes. 
**, p<0.0005; Mann-Whitney test. Exact P values are listed as follows: down-reg versus 
expressed P = 9.209248e-31, up-reg versus expressed P = 0.002601427. B, In short genomic 
windows of 10 and 20 kb only downregulated genes lie closer to a heart enhancer. *, p<0.01; 
Proportions test. Exact P values are listed as follows: in the 10 Kb window, down-reg versus 
expressed P = 3.83E-11, and up-reg versus expressed P = 0.347; in the 20 Kb window, down-
reg versus expressed P = 1.8E-27, and up-reg versus expressed P = 0.235. n.s.: non-
significant. 
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We next questioned whether there were other differences between the upregulated and 
downregulated genes from the Ctcf KO versus control comparison. We therefore 
regarded the gene distribution, i.e., how far away or close were the DEG relative to 
other genes in the genome. To do this, we again used the TSS of each gene as a fixed 
position, only this time we measured the distance (in kb) between the TSS of the DEG 
and the TSS of the immediately neighboring upstream and downstream genes. We 
summed both distances for each gene and obtained a single value, the total distance 
(expressed in kb) for each gene. We then compared this value (the total distance) 
between upregulated and downregulated genes. We again observed a difference 
between these two datasets. The downregulated genes presented a larger distance to 
neighboring genes than the upregulated genes (Fig.  23).  
 
Fig. 23. Distance between the DEG from the Ctcf KO versus control comparison with their 
neighboring genes. 
4. Ctcf deletion affects the expression of tandemly arranged 
genes  
Once we had established a global view of the consequences for gene transcription of 
Ctcf deletion in the embryonic heart, we sought to further explore the role of Ctcf in 
gene regulation in heart development by focusing on specific examples. Ctcf can act as 
an insulator, and the CTCF binding sites can act by delimiting regulatory landscapes 
(Narendra et al. 2015; Yang and Corces 2012). One way to test the role of Ctcf as an 
insulator is to examine the expression pattern (and levels) of gene pairs that are in 
tandem (next to each other), differentially expressed in control conditions, and that 
have at least one CTCF binding site between them that could explain the differential 
expression. Several gene pairs met these criteria. We selected the following four gene 
pairs to examine the role of Ctcf as an insulator, and analyzed their expression by RNA 
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in situ hybridization: Tnnt1-Tnni3 (Fig. 24A), Tnni2-Tnnt3 (Fig. 15A), Tbx2-Tbx4 (Fig. 
16A) and Tbx3-Tbx5 (Fig. 27A).  
The troponin complex plays a role in the regulation of striated muscle contraction. It 
has three subunits: troponin I (Tnni), Troponin T (Tnnt) and Troponin C (Tnnc), they are 
the inhibitory, tropomyosin-binding and calcium-binding subunit respectively (Katrukha 
2013). Each subunit has homologous that are tissue specific. We focus here in four 
troponin genes. Tnni3 is cardiac specific and is expressed in all myocardium 
(Christoffels et al. 2006; Christoffels et al. 2009; Zhu et al. 1995). Tnnt1 is transiently 
expressed in the developing heart, but not exclusively. In the heart it is expressed at 
lower levels in comparison to Tnni3, and Tnnt1 expression pattern is not uniform within 
the myocardium, it is not expressed at the same levels in all myocardium (Barton et al. 
2004; Q. Wang et al. 2001). There is one study that detects Tnni2 in the developing 
heart (Zhu et al. 1995). It is expressed at lower levels in comparison to Tnni3. Tnni2 
expression pattern is not uniform and is restricted to the compact myocardium (Zhu et 
al. 1995). Tnnt3 is expressed in non-cardiac striated muscle (Q. Wang et al. 2001). 
Tnnt1, Tnni2 and Tnnt3 are upregulated in the heart in cardiomyopathies (Huang et al. 
2008; Katrukha 2013; Petchey et al. 2014).  
The troponin gene pairs analyzed here presented significantly changed expression 
levels in the Ctcf KO versus control comparison. Interestingly, in both gene pairs, one 
was downregulated and the other one was upregulated (Tnnt1-Tnni3 and Tnni2-Tnnt3, 
respectively). 
 
Fig. 24. Tnnt1 and Tnni3 expression upon Ctcf deletion. 
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A, Genomic region containing Tnnt1 and Tnni3 (mm9, chr7:4,433,080- 4,493,651) together with 
the distribution of CTCF binding sites in the heart. Troponin genes are highlighted in black. B-E, 
In situ hybridization in sections of E10.5 control and KO hearts for Tnnt1 (B,C) and Tnni3 (D,E). 
RA: right atrium, RV: right ventricle, AVC: atrioventricular canal, LA: left atrium, LV: left ventricle. 
Scale bar is 200 μm. 
RNA in situ hybridization at E10.5 showed that Tnnt1 was expressed mainly in the 
compact myocardium of the ventricle and in the left atrium (Fig. 24B). We found that 
indeed Tnni3 was expressed in all the compact myocardium, the trabeculae and in both 
atria (Fig. 24D). Tnnt1 expression was drastically decreased in the Ctcf KO (Fig. 24C), 
and Tnni3 expression was modestly increased (Fig. 24E). 
We found that in the control, Tnni2 was expressed in the ventricles and atria (Fig. 25B) 
and Tnnt3 was expressed as a few scattered dots only in the atria (Fig. 25D). In the 
Ctcf KO, Tnni2 expression was dramatically decreased (Fig. 25C), whereas Tnnt3 
expression was increased only in the atria (Fig. 25E).  
Results from RNA in situ hybridization of the troponin genes here analyzed fitted well 
with those from the RNAseq analysis for the Ctcf KO versus control comparison. Given 
that these genes presented divergent expression patterns, we hypothesized that they 
belong to different regulatory domains. Moreover, CTCF can help to delimitate 
regulatory domains (Narendra et al. 2015; Yang and Corces 2012), in other words to 
form and/or maintain boundaries. If the regulatory domains were separated by CTCF, 
we would expect ectopic expression patterns of at least one member of the gene pairs. 
This could be explained because without the insulator, inadequate regulatory elements 
could act upon the inappropriate gene. We only found up or downregulation of genes in 
their endogenous domains of expression. Ctcf loss does influences expression of the 
four troponin genes analyzed here, but it does not act by insulating the regulatory 
elements in the troponins gene pairs.  
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Fig. 25. Tnni2 and Tnnt3 expression upon Ctcf deletion. 
A, Genomic region containing Tnni2 and Tnnt3 (mm9, chr7:149,623,608-149,703,181) together 
with the distribution of CTCF binding sites in the heart. Troponin genes are highlighted in black. 
B-E, In situ hybridization in sections of E10.5 control and KO hearts for Tnni2 (B,C) and Tnnt3 
(D,E). RA: right atrium, RV: right ventricle, AVC: atrioventricular canal, LA: left atrium, LV: left 
ventricle. Scale bar is 200 μm. 
The T-box transcription factors are a group of genes, at least 18, that play a role in 
heart development (Clowes et al. 2014). We focus here in four genes that are arranged 
in tandem by pairs (Tbx2-Tbx4) and (Tbx3-Tbx5). This genomic arrangement is 
conserved in evolution (Horton et al. 2008). Tbx5 is expressed in both atria and left 
ventricle, and it activates chamber myocardial gene program (Greulich et al. 2011). 
Haploinsufficiency of this gene causes Holt-Oram syndrome (Bruneau et al. 1999). 
Tbx2 and Tbx3 represses chamber specific genes and block chamber formation. They 
are expressed in non-chamber territories in the heart, like atrioventricular canal (Tbx2 
and Tbx3) and out flow tract (Tbx2) (Clowes et al. 2014; Hoogaars et al. 2004). Tbx4 is 
expressed in the developing heart, but no role in heart morphogenesis has been so far 
described (Chapman et al. 1996; Krause et al. 2004). 
These four genes were not differentially expressed in the Ctcf KO versus control 
comparison. Still, we wished to analyze if subtle changes in expression could be 
detected by RNA in situ hybridization. To analyze Tbx gene expression, we performed 
RNA in situ hybridization at two developmental stages, E9.5 and E11.5, to evaluate 
whether changes in expression could be detected at either or both stages.  
In the control, Tbx2 was expressed in the atrioventricular canal (Fig. 26B-D and 
(Stennard and Harvey 2005)). No expression changes were detected in KO hearts at 
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E9.5 (Fig. 26B-D), and only subtle ectopic expression in the right ventricle at E11.5 was 
detected (arrowheads, Fig. 26D-E). Tbx4 is associated with limb development, 
however, it has also been detected in the heart by in situ hybridization (Chapman et al. 
1996) and it was also detected in our RNAseq (appendix C). We were only able to 
detect extremely subtle Tbx4 expression in the heart in controls, with no obvious 
changes in KOs (Fig. 26F-I).  
 
Fig. 26. Tbx2 and Tbx4 expression upon Ctcf deletion. 
A, Genomic region containing Tbx2 and Tbx4 (mm9, chr11:85,641,154-85,731,359) together 
with the distribution of CTCF binding sites in the heart. Tbx genes are highlighted in black. B-I, 
In situ hybridization in sections of control and KO hearts for Tbx2 at E9.5 (B,C) and E11.5 (D,E). 
Arowheads at D and E show subtle Tbx2 upregulation; and Tbx4 at E9.5 (F,G) and E11.5 (H,I). 
RA: right atrium, RV: right ventricle, IVS: interventricular septum, AVC: atrioventricular canal, 
LA: left atrium, LV: left ventricle. Scale bar is 200 μm. 
Finally, we examined the expression of the Tbx3-Tbx5 gene pair. Tbx3 was expressed 
in the atrioventricular canal in control mice, and we found that its expression was 
unaltered upon Ctcf deletion at any stage (Fig. 27B-E). In control hearts, Tbx5 was 
expressed in both atria and also in the left ventricle. In Ctcf KO hearts, its expression 
was decreased only at E11.5, with no obvious changes in levels or pattern of 
expression at E9.5 (Fig. 27F-I). Similar to our results with the troponin genes, we failed 
to detect ectopic expression in the Ctcf KO hearts of any of the Tbx genes analyzed. 
While Tbxs genes also presented characteristics that make them appealing candidates 
to test the role of Ctcf as an insulator, again we found that Ctcf seems not to act as an 
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insulator to separate the adjacent regulatory domains of the Tbx gene pairs here 
analyzed. 
 
Fig. 27. Tbx3 and Tbx5 expression upon Ctcf deletion. 
A, Genomic region containing Tbx3 and Tbx5 (mm9, chr5:120,107,016-120,338,997) together 
with the distribution of CTCF binding sites in the heart. Tbx genes are highlighted in black. B-I, 
In situ hybridization in sections of control and KO hearts for Tbx3 at E9.5 (B,C) and E11.5 (D,E); 
and Tbx5 at E9.5 (F,G) and E11.5 (H,I). RA: right atrium, RV: right ventricle, AVC: 
atrioventricular canal, LA: left atrium, LV: left ventricle. Scale bar is 200 μm.  
5. Ctcf alters the expression of genes in the IrxA cluster 
To further characterize the role of Ctcf in gene regulation, we focused our attention on 
Irx4, a chamber identity cardiac transcription factor that belongs to the IrxA cluster (Bao 
et al. 1999; Gomez-Skarmeta and Modolell 2002). This cluster includes three genes: 
Irx1, Irx2 and Irx4. All genes from this cluster are expressed in the heart (Kim et al. 
2012). Only Irx4 was differentially expressed in Ctcf KO versus control heart 
comparisons, and it was downregulated (Fig. 28). Irx1 and Irx2 showed no significant 
changes, however they presented the tendency to be upregulated (Fig. 28). We thus 
performed RNA in situ hybridization of Irx1, Irx2 and Irx4 genes at E9.5 and E11.5. Irx4 
is strongly expressed in the ventricles, whereas Irx1/Irx2 are expressed in the 
interventricular septum of the developing heart (Kim et al. 2012). At E9.5, Irx1 and Irx2 
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showed a subtle expansion of their expression pattern in the ventricles (arrows in Fig. 
29B,C), whereas Irx4 showed no changes in expression levels at this stage (Fig. 29D). 
At E11.5, Irx1 RNA in situ hybridization also showed a subtle expansion in its 
expression pattern (Fig. 29E,H); Irx2 did not present any changes in its expression 
pattern (Fig. 29F), and Irx4 showed a dramatic decrease in expression levels (Fig. 
29G,I). 
 
Fig. 28. IrxA cluster dysregulation upon Ctcf deletion. 
Irx4 is the only member of the IrxA cluster found to be downregulated. The other members (Irx1 
and Irx2) do not change, and their three immediate neighbors (Ndufs6, Mrpl36 and Lpcat1) are 
upregulated.  
Further inspection of the RNAseq data showed that the three genes telomeric to the 
IrxA cluster (Fig. 30A), Ndufs6, Mrlp36 and Lpcat1, were upregulated (Fig. 28). We 
performed RNA in situ hybridization of the first two genes, Ndufs6 and Mrlp36. Only 
Ndufs6 has been detected in the heart by RNA in situ hybridization (Smith et al. 2014). 
Our results showed that both genes were highly expressed in the whole heart and in 
the embryo (Fig. 31B,D), and only Ndufs6 (Fig. 30C,E) presented a subtle upregulation 
in KO embryos by in situ. 
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Fig. 29. IrxA cluster altered gene expression at E9.5 upon Ctcf deletion 
A, Genomic region containing the IrxA cluster (mm9, chr13:71,984,688-73,504,230) together 
with the distribution of CTCF binding sites in the heart. B-D. In situ hybridization on sections of 
E9.5 control and KO hearts for Irx1 (B), Irx2 (C); and Irx4 (D) Arrows in B and C show ectopic 
expression of Irx1 and Irx2 respectively. E-I, In situ hybridization in sections of E11.5 control 
and KO hearts for Irx1 (E), Irx2 (F); and Irx4 (G). Close up views show the ectopic expression of 
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Irx1 (H, arrows) and downregulation of Irx4 (I) RA: right atrium, RV: right ventricle, IVS: 
interventricular septum, AVC: atrioventricular canal, LA: left atrium, LV: left ventricle. Scale bar 
is 200 μm. 
 
 
Fig. 30. Neighbors of the IrxA cluster with altered gene expression at E11.5 upon Ctcf 
deletion. 
A. Genomic region containing the IrxA cluster and neighboring genes Ndufs6 and Mrpl36 (mm9, 
chr13:71,984,688-73,504,230) together with the distribution of CTCF binding sites in the heart. 
B-E. In situ hybridization in sections of E11.5 control (B,D) and KO hearts (C,E) for Ndufs6 and 
Mrlp36 respectively. RA: right atrium, RV: right ventricle, IVS: interventricular septum, AVC: 
atrioventricular canal, LA: left atrium, LV: left ventricle. Scale bar is 200 μm. 
The IrxA cluster has a homologous cluster, IrxB, and previous evidence from zebrafish 
has shown that CTCF might have a role in separating the first two genes, Irx3 and Irx5, 
from the most telomeric gene of the cluster, Irx6 (Tena et al. 2011). Irx3 is expressed in 
the trabecular region of the ventricles, whereas Irx5 and Irx6 are expressed in the 
endocardium of the ventricles and atria (Kim et al. 2012). Although none of these 
genes were differentially expressed in the RNAseq analysis, we performed RNA in situ 
hybridization of the three genes at E11.5, which was the stage at which more dramatic 
changes were found in the expression of IrxA cluster genes in the Ctcf KO hearts. 
However, no member of the cluster presented a change in expression upon Ctcf loss at 
E11.5 (Fig. 31). 
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6. The three dimensional structure of the IrxA cluster  
The Irx genes have a conserved genomic organization that occupies around 1 Mb 
(Gomez-Skarmeta and Modolell 2002). Previous work has shown that this conserved 
genomic organization is related to Irx gene regulation since the large genomic region in 
each cluster, with only three genes, harbors enhancers that are possibly shared among 
genes in the clusters (de la Calle-Mustienes et al. 2005; Tena et al. 2011). Moreover, 
3C experiments in the IrxA cluster showed that physical interactions occur between 
several enhancers and the Irx1 and Irx2 promoters, and that these interactions are 
tissue specific (Tena et al. 2011). This raised the possibility that not all the members of 
the cluster share the same regulatory elements. Besides enhancer-promoter 
interactions, promoter-promoter interactions between Irx1 and Irx2 were also found, 
and in a tissue independent manner. Moreover, the Irx1/Irx2 promoter interaction was 
conserved among vertebrates and it was suggested to be CTCF-dependent (Tena et 
al. 2011).  
 
Fig. 31. IrxB cluster gene expression at E11.5 upon Ctcf deletion. 
A, Genomic region containing the IrxB cluster (mm9, chr8:94,275,320-95,219,217) together with 
the distribution of CTCF binding sites in the heart. B-G, In situ hybridization in sections of E11.5 
control and KO hearts for Irx3 (B,C) Irx5 (D,E), and Irx6 (F,G). RA: right atrium, RV: right 
ventricle, IVS: interventricular septum, AVC: atrioventricular canal, LA: left atrium, LV: left 
ventricle. Scale bar is 200 μm 
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However, the lack of interaction between evolutionarily conserved enhancers from the 
IrxA cluster and Irx4 (Tena et al. 2011) remains an unresolved issue. To get further 
insight into the 3D structure of the IrxA cluster, we carried out 4C-seq (Splinter et al. 
2012; van de Werken et al. 2012a) using the promoters of Irx1, Irx2, Irx4 and the first 
downstream gene of the cluster, Ndufs6, as viewpoints.  
We observed that the IrxA cluster was divided into two interacting regions (Fig. 32). 
The centromeric part of the cluster contains Irx1 and Irx2 genes, and they presented a 
very similar interaction pattern that diminished at a similar point. Irx4 is found in the 
telomeric part of the cluster. Irx4 and Ndufs6 had similar interaction patterns. Also, the 
Irx1 and Irx2 interacting region is larger than the region containing Irx4 and Ndufs6.  
The division of the cluster fits with the previous suggestion that the members of the 
cluster could share some enhancers because they have few partially overlapping 
expression territories (Cavodeassi et al. 2001; Gomez-Skarmeta and Modolell 2002). 
However, Irx1 and Irx2 share more expression territories. Thus it is highly likely that 
these two genes share more regulatory elements between themselves that either one 
with Irx4. Our results support this possibility as we can see in the 4C-seq profile that 
these two genes present similar interacting profile. 
7. Loss of CTCF disrupts the chromatin structure of the IrxA 
cluster 
Given the observation that CTCF loss downregulated Irx4 and altered the expression of 
other genes in the cluster (Fig. 29), we next questioned whether Ctcf deletion also 
altered the 3D structure of the IrxA cluster. To address this, we carried out 4C-seq in 
Ctcf KO hearts using the same four viewpoints used in the control hearts: Irx1, Irx2, 
Irx4 and Ndufs6. We observed that the 3D structure of Irx1, Irx2 and Ndufs6 (Fig. 33) 
was basically preserved upon Ctcf loss, and that only Irx4 presented significant 
changes in interactions between KO and control hearts (Fig. 34).  
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Fig. 32. The IrxA cluster is divided into two distinct interaction domains. 
Chromatin interactions in the IrxA cluster in E11.5 control (wt) hearts revealed by 4C-seq using 
viewpoints in the promoters of Irx1, Irx2, Irx4 and Ndufs6 (vertical purple lines) (mm9; 
chr13:69,320,289-76,541,363). n>3 for each sample. 
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Fig. 33. Effect of Ctcf deletion on the 3D genomic structure of the IrxA cluster.  
Chromatin interactions in the IrxA cluster in E11.5 control (wt) and KO (KO) hearts revealed by 
4C-seq using viewpoints in the promoters of Irx1, Irx2, Irx4 and Ndufs6 (vertical purple lines). 
The binding profile of CTCF in 8-week-old hearts is shown at the top for reference (mm9; 
chr13:72,027,675-73,679,627). n>3 for each sample.  
We detected changes in interactions established by the promoter of Irx4 with four 
specific genomic regions, two of them showing increased interaction in the Ctcf KO and 
two showing decreased interaction. The regions with increased interactions in the Ctcf 
KO contained a CTCF binding site (i) or, in the second case (ii), a previously described 
neural enhancer that has been shown to interact with the promoters of Irx1 and Irx2 but 
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not with the promoter of Irx4 (Tena et al. 2011). The regions showing a decrease in the 
interactions with the Irx4 promoter in the Ctcf KO surround the gene and contain CTCF 
binding sites. The region centromeric to the Irx4 promoter (iii) harbored a candidate 
CTCF site that could be involved in separating the interaction and regulatory domain of 
the IrxA cluster. Indeed, we have shown that this region has insulator activity and 
prevents communication between regulatory elements in an in vivo zebrafish functional 
assay (appendix E). The second region with decreased interactions (iv) harbored 
several CTCF sites located at the 3’ end of the Lpcat1 gene. Although not statistical 
significant, two other interesting sites that showed decreased interaction with the Irx4 
promoter were the two downstream CTCF binding sites (* and **). The reason this sites 
are interesting is because they could be the limits of the Irx4 regulatory landscape. In 
summary, the chromatin structure of the IrxA cluster shows clear alterations upon Ctcf 
deletion, and provides valuable insight to define the potential regulatory domain 
specific for Irx4 in the heart.  
 
Fig. 34. Changes in the genomic structure of the Irx4 locus upon Ctcf deletion. 
4C-seq profiles using the Irx4 promoter viewpoint (vertical purple line) in control (wt) and Ctcf 
KO (KO) embryonic hearts. Bins showing significant differences are indicated by short black 
lines and are boxed together, with shading in green when the interaction is gained in Ctcf KO (i, 
ii) and in red when it is lost (iii, iv). Yellow shading (*, **) highlights regions encompassing CTCF 
binding sites that show diminished interaction with the Irx4 promoter in Ctcf KO, but that do not 
reach statistical significance (mm9: chr13:73,068,893-73,676,056). n=5 and n=3 for the control 
and Ctcf KO, respectively. 
8. CTCF delimits the cardiac regulatory domain of Irx4 
The detailed analysis of the interaction map for Irx4 allowed us to delineate its putative 
regulatory landscape between the CTCF binding sites that showed reduced interaction 
in the Ctcf KO (Fig. 34). A strong prediction that follows is that regulatory elements 
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driving Irx4 expression in the developing heart should be contained within this region. 
There are several well-characterized histone marks that help to locate active and 
inactive regions of the chromatin and identify those with potential enhancer activity 
(Shen et al. 2012).  
 
Fig. 35. Irx4 putative regulatory landscape. 
A, UCSC genome browser view of the Irx4 region (mm9; chr13:73,281,240-73,660,195) 
showing (from top to bottom) the distribution of CTCF and histone modifications for active 
enhancers (H3K4me1 and H3K27ac) in the embryonic heart, limb and brain. Fragments 
selected for transgenic assays are highlighted in blue. B, LacZ reporter activity driven by the 
selected fragments (Frag 1-Frag 7) in transgenic embryos at E10.5 (Frag 1, 2, 4-7) or E11.5 
(Frag 3). C, Higher magnification views of the boxed regions in B, showing reporter activity in 
the heart. 
H3Kme1 marks active and poised enhancers while H327ac marks active elements 
(Rada-Iglesias et al. 2011). Within our putative Irx4 regulatory landscape, we examined 
these two histone profiles in three mouse embryonic tissues: heart, brain and limb, as 
these tissues are expression territories of IrxA cluster genes during development 
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(Bosse et al. 1997). Based on the distribution of histone marks and excluding promoter 
regions, we chose seven candidate fragments to test their regulatory potential in a 
transient transgenic assay (Fig. 35A). All selected fragments presented H3K4me1 and 
H3K27ac histone marks in the heart. Only fragments 1, 4 and 5 exclusively presented 
this histone marks combination in the heart. Fragments 2 and 7 also presented this 
combination in the limb and H3K4me1 in the brain. Finally fragments 3 and 6, also 
presented H3K4me1 in the limb. No fragment presented H3K427ac in the brain (Table 
15). We found that all seven fragments tested drove β-galactosidase expression in the 
embryo, demonstrating that these fragments have enhancer activity (Fig. 35B). 
However, only four of the regulatory elements (57%) induced β-galactosidase 
expression in the heart (Fig. 35C). These results show that there are several elements 
with heart enhancer potential inside the Irx4 genomic region delimited by CTCF binding 
sites. Although all fragments drove expression in the embryo, only fragment 1 behaved 
as expected based on the histones profile. It presented the histone marks combination 
exclusively in the heart and we only detected enhancer activity in this organ. The rest 
of the fragments drove the reporter gene expression at least in one expected territory 
(Table 15).  
9. Ctcf is necessary for the proper 3D assembly and functioning 
of the Irx4 regulatory landscape 
RNAseq and in situ hybridization showed that Irx4 expression was downregulated in 
Ctcf KO hearts. Additionally, the interaction maps of Irx1, Irx2 and Irx4 promoters 
obtained by 4C-seq showed that the breakpoint of the interacting profiles occurred near 
the first centromeric CTCF binding site from Irx4 (Fig. 34 iii). This site showed a 
decrease in interaction with the Irx4 promoter in Ctcf KO hearts, and also showed 
insulator activity (appendix E). Taken together, these results indicate that this CTCF 
binding site (Fig. 34 iii) is a strong candidate that could demarcate the two interacting 
regions inside the IrxA cluster. Besides, when Ctcf is deleted, we observed a decrease 
in interaction between this site and the Irx4 promoter, and we also observed Irx4 
downregulation. Thus, this site could be implicated in the 3D assembly of the Irx4 
landscape and in regulating its expression.  
To gain further insight about this site in the structure of the locus, we performed 4C-seq 
using this site (Fig. 34 iii) as a viewpoint in control and Ctcf KO hearts. Although no 
significant differences were found, we detected regions showing weaker interactions, 
one with the Irx4 promoter itself (*; Fig. 36), and with further CTCF sites downstream of 
Irx4 (**, ***; Fig. 36). We also tested the interactions established from fragment 1 
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(frag1), that shows enhancer activity in the heart (Fig. 35B,C). We obtained similar 
results: reduced interaction with the Irx4 promoter (*; Fig. 36), and with only one of the 
downstream CTCF binding sites (**; Fig. 36). Thus, Ctcf is necessary to form the 
interaction between this CTCF binding site and the Irx4 promoter, and this interaction 
could be necessary to properly express Irx4 in the developing heart.  
Table 15. Correlation of histone marks and enhancer activity in transient transgenic 
embryos 
 
 
Fig. 36. Ctcf deletion impacts the 3D structure of the Irx4 locus. 
4C-seq in control (wt) and KO (KO) hearts using the CTFC binding site located between Irx2 
and Irx4, and the Frag1 enhancer as viewpoints (purple lines). Both viewpoints showed a 
decrease in interaction with the Irx4 promoter (*) and the first (**) Ctcf binding site downstream 
Irx4. Only CTCF BS showed a decrease in interaction with a second CTCF binding site (***) The 
binding profile of CTCF (Shen et al. 2012) is shown at the top for reference (mm9; 
chr13:73,068,893-73,676,056). CTCF BS = CTCF binding site; Frag1 = fragment 1 n=2 for each 
sample. 
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The above results strongly suggest that the CTCF binding site between Irx2 and Irx4 
(Fig. 34 iii) is involved in the 3D structure of the Irx4 loci (Fig. 36). To determine if this 
site was also required for proper Irx4 expression, we used the CRISPRs/Cas9 genome 
editing system to delete this CTCF binding site in a mouse transient transgenic assay 
(Fig. 37). 
 
Fig. 37. Location of gRNAs used for the deletion of the Irx2/Irx4 intergenic CTCF binding 
site.  
Locations of the three guideRNAs used to delete the CTCF binding site. Two guide 
combinations were used: g5.3 and g3, and g5.4 and g3. 
We designed three gRNA (guides RNA, see methods for details) that were used in two 
combinations (g5.3 and g3; g5.4 and g3, Fig. 38) to target the CTCF binding site (Fig. 
34 iii). One combination gave rise to a 1.3 kb deletion and the other combination gave 
rise to a smaller deletion of 779 bp (g5.3 and g3; g5.4 and g3, respectively).  Each 
combination of gRNAs together with Cas9 protein was microinjected into the 
pronucleus of E0.5 mouse embryos. After transfer to foster CD1 mothers, they were 
collected at E9.5 or E10.5, processed for in situ RNA hybridization and their yolk sacs 
used for genotyping. Our genotyping strategy identified the presence of deleted alleles 
by PCR product size. The deleted allele from those embryos obtained with g5.3 and g3 
combination had a PCR product of 829 bp, and the deleted allele from those embryos 
obtained with the g5.4 and g3 combination had a PCR product of 234 bp. Except for 
one embryo, we also detected the wildtype allele in all embryos genotyped, surely due 
to the expected mosaicism of the deletion at early stages. The sequencing confirmed 
the expected deletion and also showed that it was highly consistent (Fig. 38).  
RESULTS 
 
108 
 
 
Fig. 38. CTFC binding site deletion using the CRISPR/Cas9 system. 
A, Genomic sequence from embryos carrying the deletion generated using the combination of 
g5.4 and g3 gRNAs (779 bp deletion). B, Genomic sequence from embryos carrying the 
deletion generated using the combination of g5.3 and g3 gRNAs (1374 kb deletion). 
Finally, to evaluate whether Irx4 expression was altered when this CTCF binding site 
(Fig. 34iii) was deleted, we performed whole mount Irx4 in situ hybridization in embryos 
that were PCR-positive for the deletion, using CD1 embryos controls (referred here to 
as wild-type). We also performed in parallel Irx4 in situ hybridization for Ctcf KO 
embryos and its appropriate control in order to have a reference for Irx4 
downregulation upon Ctcf deletion. We found that Irx4 was downregulated in the 
embryos that had a deletion of the CTCF binding site (Fig. 39A-D). This downregulation 
was more conspicuous than in Cfcf KO embryos (Fig. 39E-H). These results indicate 
that proper Irx4 expression requires this Ctcf binding site (Fig. 34 iii). Collectively, we 
conclude that during heart development, the Irx4 locus presents a CTCF-mediated 3D 
structure, which is required for the proper expression of the IrxA cluster and 
neighboring genes. 
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Fig. 39. The Irx2/Irx4 intergenic CTCF binding site is necessary for proper Irx4 
expression. 
A-D, Irx4 whole mount in situ hybridization of E10.5 embryos where the Irx2/Irx4 intergenic 
CTFC binding site has been deleted with the CRISPR/Cas9 system A, is a CD1 embryo (wild 
type). C, is the genome-edited embryo (CTCF BS del). B and D show close-up views of the 
hearts where Irx4 downregulation upon CTCF site deletion is better appreciated. E-H, Irx4 
whole mount in situ hybridization of E10.5 embryos where the Ctcf gene was deleted using the 
Cre/LoxP system. E, is a control (Ctcffl/fl) embryo. G, is a Ctcf KO (Ctcffl/fl;Nkx2.5-Cre) embryo. 
F and H are close-up views of E and G respectively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
110 
 
 
 
 
 111 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 112 
 
 
 
 
 
 
 
 
DISCUSSION 
 
113 
 
Our understanding of the importance of 3D genomic structure for gene regulation is 
rapidly increasing through advances in new technologies (Bonora et al. 2014). The role 
of 3D structure during in vivo heart development, however, remains relatively 
unexplored (van Weerd et al. 2014). Since Ctcf is considered a master genome 
organizer in mammals (Phillips and Corces 2009) and increasing evidence supports 
the relevance of this protein in 3D structure (Ong and Corces 2014), we investigated 
the role of 3D structure for gene regulation during heart development by deleting Ctcf in 
developing cardiac tissue.  
1. Ctcf is necessary for proper heart development 
Because the germline Ctcf full knockout is lethal (Fedoriw et al. 2004; Moore et al. 
2012; Wan et al. 2008), it must be conditionally deleted (Heath et al. 2008). We show 
here that the conditional deletion of Ctcf in the early cardiac lineage is embryonic-
lethal, which is in accord with observations in other systems with tissue-specific 
deletion of Ctcf eg, in post-mitotic projection neurons (Hirayama et al. 2012), and early 
nervous system development (Watson et al. 2014). For example in B and T cells, 
proliferation, a key step in development, is impaired (Heath et al. 2008; Ribeiro de 
Almeida et al. 2011). Furthermore, in Th2 cells, the cytokine that confers Th2 cell 
identity is downregulated (Ribeiro de Almeida et al. 2009), and in myeloid cells, 
macrophage differentiation is impaired (Nikolic et al. 2014). In the early nervous 
system, deletion of Ctcf between E8 and E9 was found to reduce the size of the 
telencephalic and retinal structures, and no pups were recovered at birth. Moreover, 
shortly after the onset of deletion, at E11, an increase in apoptosis was detected. 
Deletion at later stages (E11) in the telencephalon produced a similar phenotype, but 
with a delay because the increase in apoptosis occurred at E14.5 and death was 
neonatal (Watson et al. 2014). Ctcf deletion in the oocyte delays the onset of mitosis 
and reduces meiosis competence. In addition, after fertilization, the second mitotic 
division is delayed, and zygote genome activation is perturbed. Embryos die before the 
blastocyst stage by apoptosis (Wan et al. 2008). 
Because deletion of Ctcf in other developmental systems such as the oocyte, the limb 
and the nervous system, is known to increase apoptosis (Soshnikova et al. 2010; Wan 
et al. 2008; Watson et al. 2014) and leads to a decrease in cell proliferation in T cells 
(Heath et al. 2008; Ribeiro de Almeida et al. 2011), we analyzed these parameters in 
our conditional model. We chose to do so at the midpoint between the onset of deletion 
and embryonic death. In contrast to other systems, we failed to find any alterations in 
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these two processes. However, we do not rule out the possibility that apoptosis could 
be triggered later, perhaps at a time closer to embryonic death.  
Our findings together with those of previous studies highlight the relevance of Ctcf in 
development; however, the final outcome of Ctcf deletion is not shared by all systems, 
as shown by the lack of effect in cellular processes such as cell proliferation or 
apoptosis ((Heath et al. 2008; Hirayama et al. 2012; Ribeiro de Almeida et al. 2011) 
and this work). Moreover, the phenotypes are different in each system studied, 
suggesting that the role of this protein is tissue specific. Indeed, it is interesting that the 
deletion of the same protein produces tissue-specific phenotypes, and that CTCF 
target genes such as Myc do not always respond to the absence of Ctcf (Wan et al. 
2008). Although development is altered in most of the systems studied so far, it is 
unclear how tissue specificity is achieved. 
Ctcf is known to associate with other proteins (Defossez et al. 2005; Donohoe et al. 
2007), and posttranslational modifications regulate its binding to the chromatin 
(Klenova et al. 2001). Clearly, these events might be important for establishing tissue-
specific roles for this protein. For example, the transcription factor YY1 can associate 
with CTCF and this associated complex plays a role in X chromosome inactivation 
(Donohoe et al. 2007). Interestingly, YY1 has a role in cardiac morphogenesis 
(Beketaev et al. 2015). However, deletion of this protein using the same Nkx2.5-Cre 
driver as used in this project altered cardiac cell proliferation and apoptosis (Beketaev 
et al. 2015), excluding it as a candidate to confer CTCF tissue-specific activity at least 
in the developing heart. In other systems, such as in B cells, these two proteins seem 
to interact in the same process of long-range interaction (Atchison 2014; Ribeiro de 
Almeida et al. 2011). Cohesin, another architectural protein, can bind to DNA alone or 
together with CTCF, mediator or Nipbl. In ES cells, the association of cohesin with 
Nipbl and mediator is related to the maintenance of the transcriptional program (Kagey 
et al. 2010). Thus, the search for CTCF cofactors and other posttranslational 
modifications that could influence its binding to DNA and/or its activity will help to better 
define its tissue specifificity. 
2. Ctcf is necessary to activate the cardiac transcriptional 
program 
To understand the role that Ctcf might play in heart development, we examined global 
transcriptional changes in our heart Ctcf KO model. GO term analysis of the 
comparison between Ctcf KO and control hearts showed that the GO terms related to 
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heart development and a group of genes related to developmental pathways such as 
Notch, TGFbeta, EGF/ErbB and BMP were present only in the downregulated genes in 
the Ctcf KO hearts. This suggests that in heart development, Ctcf is necessary to 
activate and/or maintain the cardiac transcriptional program. The upregulated genes 
included GO terms related to general metabolism. This dataset included ribosomal and 
mitochondrial proteins. Although no morphological defects were detected at the stage 
when we performed the RNAseq (E10.5), it seems that the downregulation of the 
cardiac transcriptional program is coincident with a metabolic change. 
Other cases have been reported where Ctcf is necessary for activating transcription of 
genes required for development or function of the tissue studied (Delgado-Olguin et al. 
2011; Heath et al. 2008; Hirayama et al. 2012; Ribeiro de Almeida et al. 2011). Among 
these, two published studies analyzed global transcriptional changes using microarray 
protocols. In one study, Ctcf was depleted in post-mitotic neurons (Hirayama et al. 
2012), and in the other study Ctcf was knocked-down in zebrafish using morpholinos 
(Delgado-Olguin et al. 2011; Hirayama et al. 2012). In Ctcf-deficient post-mitotic 
neurons, genes related to cell adhesion, biological adhesion, behavior and post-
embryonic development, all of which are associated with neural differentiation, were 
altered. The authors of this study focused on a group of genes, the protocadherins, 
because several members of this cluster are related to neural development and were 
downregulated (Hirayama et al. 2012). In the zebrafish model, several developmental 
GO terms were altered, and the authors focused on muscle development because it 
was in the top three GO terms detected. In contrast to our study, genes related to 
muscle development were up- and downregulated in Ctcf knocked-down zebrafish. 
This type of result also occurs in Ctcf-deleted macrophages, and genes related to 
macrophage function and development are up- and downregulated (Nikolic et al. 2014).  
Collectively, these findings indicate that Ctcf regulates transcription and interestingly 
this occurs in a tissue-specific manner. The transcriptional changes in four systems, 
the heart (this work), limb, oocyte and cortex, are compared in Fig. 40. It should be 
noted that our DEG set was obtained from RNAseq analysis, whereas the DEG sets in 
the other systems were from microarrays, and consequently the total number of genes 
is different. Nonetheless, we would have expected that the DEG detected in the 
microarrays would be also found in our DEG from the RNAseq, however, this was not 
the case. The comparison shows that these systems share very few genes that are 
altered upon Ctcf deletion. This finding also strengthens the concept that CTCF 
displays tissue specificity. As discussed above, cofactors and posttranslational 
modifications could be involved in the tissue specificity of CTCF. The transcriptional 
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data suggest that this might involve transcription factors related to tissue identity, either 
by directly binding to CTCF or by activating the expression of cofactors or partners that 
assist CTCF to act in a tissue specific manner.  
Additionally, in all cases studied transcription is altered globally. However, alteration of 
tissue-specific transcription programs as observed in zebrafish (Delgado-Olguin et al. 
2011) and in this work, are also apparent. Moreover, more pronounced effects were 
found in specific loci functionally relevant to the tissue where Ctcf was deleted, as was 
the case of the protocadherins in post mitotic tissues (Hirayama et al. 2012), or the IL-
10 locus in macrophages (Nikolic et al. 2014).  
CTCF is an architectural and chromatin-bound protein with many thousands of binding 
sites scattered genome-wide (Ong and Corces 2014). The presence of a CTCF binding 
site in the vicinity of a gene suggests that it might play a role in regulating gene 
expression eg, as seen in the B-globin  
 
Fig. 40. Comparsion of the transcriptional changes upon Ctcf deletion in four systems. 
We can see that the four systems are poorly overlapping. 
locus (Splinter et al. 2012). In this work, we observed that in the Ctcf KO versus control 
comparison, DEG were closer to an embryonic CTCF binding site (E14.5) than genes 
that were expressed but unchanged, suggesting that Ctcf regulates their transcription. 
We also observed that the downregulated genes were closer to a predicted heart 
enhancer (Shen et al. 2012). Thus, given that Ctcf mediates long-range interactions 
(Ong and Corces 2014) that are necessary for bringing together enhancers and 
promoters in T cells (Shih et al. 2012), B cells (Ribeiro de Almeida et al. 2011), and 
other systems (Guo et al. 2012; Hirayama et al. 2012; Splinter et al. 2006), we propose 
that Ctcf activates the cardiac transcription program in the developing heart by bringing 
together heart enhancers to target genes. 
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3. Ctcf does not always act as an insulator in its genomic 
context 
Insulators are DNA sequences that when placed between an enhancer and a promoter 
block the expression of the promoter (Wallace and Felsenfeld 2007). Several insulators 
have been described in vertebrates (Bell et al. 1999; Blackledge et al. 2007; Filippova 
et al. 2001; Giraldo et al. 2003; Majumder et al. 2006; Molto et al. 2009; Zhong and 
Krangel 1999). For the most part, insulator activity has been measured using in vitro 
methods, although some potential insulators have been tested in an in vivo zebrafish 
assay (Bessa et al. 2009).  
It was appealing to hypothesize that Ctcf binding sites between genes with divergent 
expression in the developing heart would be good candidates to examine the role of 
Ctcf as an insulator. Indeed, this genomic configuration and expression pattern would 
suggest that these tandemly arranged genes (i.e., the troponins and Tbx gene pairs) do 
not share the same regulatory elements, and therefore Ctcf would function to prevent 
inadequate crosstalk between regulatory elements of one gene to act on its 
neighboring gene. This has been shown for the divergently regulated Interleukin-3 and 
Granulocyte macrophage colony-stimulating factor genes (Bowers et al. 2009). In the 
case of the Tbx3 and Tbx5 gene pair, the interaction profile obtained by 4C-seq 
analysis was previously reported and indicated that indeed these two genes do not 
share regulatory elements, and that each one belongs to a different regulatory domain 
(van Weerd et al. 2014). Unexpectedly, our results showed that Ctcf binding sites 
located between genes with divergent expression patterns did not necessarily act as 
insulators since changes in expression patterns were not detected, only up- or 
downregulation in the same territory. Nevertheless, this does not automatically mean 
that other examples (not examined here) do have Ctcf insulator capacity.  
The same logic was used in a previous study that attributed an insulator role for Ctcf 
when placed between genes with divergent expression; however, the authors did not 
test any of their insulators, in vitro or in vivo (Xie et al. 2007). There are several 
examples where CTCF binding site inactivation by methylation leads to aberrant gene 
expression, demonstrating that those sites can act as insulators (Filippova et al. 2001; 
Flavahan et al. 2016), and others where, based on a divergent expression pattern, we 
could expect that the absence of Ctcf or disruption of its binding site would lead to 
aberrant expression of genes separated by CTCF binding sites. For example, the HoxD 
cluster genes have a very distinctive spatial and temporal expression pattern. These 
genes are located in tandem and are characteristic because they are not all expressed 
at the same time. Rather, they are expressed sequentially according to their linear 
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arrangement in the genome. Moreover, their expression along the antero-posterior axis 
is also sequential and corresponds to their order in the genome. This is termed 
collinearity (Mark et al. 1997) and ChIP-seq analysis in limbs showed that CTCF 
binding sites were present between these genes. Assuming the role of CTCF as an 
insulator, we could expect that its removal would lead to mis-expression of these 
genes. However, conditional deletion of Ctcf in the limb failed to change the expression 
pattern of any of these genes (Soshnikova et al. 2010). In the case of the beta-globin 
locus, a CTCF binding site, 3´HS1, showed enhancer blocking activity in a transgene 
assay, but when the binding site was disrupted in vivo the expression of the 
neighboring genes was unaltered (Splinter et al. 2006).  
These results suggest that the insulator activity mediated by CTCF is not the sole 
mechanism that restricts divergent expression patterns.  
There is evidence that DNA sequences that do not bind CTCF can act as insulators. 
The locus control region (LCR) in the TCR locus has several hypersensitive sites (HS). 
One of these HS binds CTCF, but several others do not. Moreover, two HS that do not 
bind CTCF (HS4 and HS6) in the TCR locus insulate three co-expressed genes, TCRα, 
TCRδ and Dad1 (Gomos-Klein et al. 2007; Magdinier et al. 2004). These genes are 
expressed in the same tissue, but at different stages during development. A similar 
case occurs in the Rxbr and Col11a2 genes; DNA sequences are found between these 
two genes that show insulator activity but do not bind CTCF (Murai et al. 2008). An Alu 
element in the K18 gene is another example (Willoughby et al. 2000). Other factors, 
such as SINE/ LINE, LTR and MIR elements, which are retrotransposable elements, 
could be responsible for isolating regulatory domains (Molto et al. 2009; J. Wang et al. 
2015). In this work, we only searched for CTCF binding sites. We cannot discard the 
presence of other insulator sequences between the genes that are responsible for the 
insulation of regulatory domains. Another possibility could be that the interaction itself 
between the genes and their enhancers is what indirectly separates the regulatory 
domains.  
4. The 3D structure of a paradigm cluster  
The iroquois genes comprise a group of genes with a very specific genomic 
organization (Gomez-Skarmeta and Modolell 2002). Current evidence indicates that 
this genomic organization is relevant for their regulation (de la Calle-Mustienes et al. 
2005; Tena et al. 2011). There are six iroquois genes distributed in two clusters, and 
each cluster has three genes. We analyzed the 3D structure of the cluster A. 
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Previous work showed that predominantly the first two members of the vertebrate 
Iroquois cluster A shared expression territories, and that Irx4 had a more divergent and 
restricted expression pattern (Christoffels et al. 2000; Houweling et al. 2001). This 
arrangement is also present in other vertebrates, including Xenopus, Medaka (Tena et 
al. 2011) and even Drosophila (Cavodeassi et al. 2001). Moreover, enhancers tested 
so far from the IrxA cluster mainly interact with Irx1 and Irx2 (Tena et al. 2011). These 
findings strongly suggest that this cluster is divided into two regulatory domains (Tena 
et al. 2011). Our present results show that indeed the IrxA cluster is divided into two 
interacting domains of unequal size. The centromeric part of the cluster contains the 
Irx1 and Irx2 genes and the telomeric part contains the Irx4 gene.  
We also performed 4C-seq analysis of Ndufs6, the first gene downstream of the cluster 
A. Ndufs6 is a subunit of mitochondrial Complex I. Considering their interaction profiles, 
Irx4 and Ndufs6 share interacting regions and must share some of the cardiac 
regulatory elements since they share expression territories as shown by RNA in situ 
hybridization. Based on the expression pattern and the genomic location of Mrlp36, we 
predict that its interaction profile will be highly overlapping at least with that of Ndufs6. 
The IrxA cluster is an example of how expression patterns together with gene location 
can give insight into genomic organization. Shared expression patterns can predict, at 
least in part, the genomic regions where the regulatory elements acting on genes will 
be. This was also observed for the Tbx3 and Tbx5 genes; the fact that they lie next to 
each other and do not share expression patterns indicated different interacting domains 
and actually that was the case (van Weerd et al. 2014). The same interaction profiles 
can delimit the genomic region in which to look for regulatory elements. Consequently, 
genomic structure can provide information about the regulation of a gene. This 
delimitation in interaction between two genomic regions is a phenomenon that occurs 
genome-wide, and the IrxA cluster is an example of a TAD or two sub-TADs. The 
median size of a TAD is 880 kb (Dixon et al. 2012); however, they are also defined by 
the reduced interaction between two genomic regions (Valton and Dekker 2016). The 
IrxA cluster very likely organizes in a single TAD since there are regulatory elements 
shared by the three members of the cluster, and the two interacting regions are sub-
TADs where enhancer-promoter interactions occur (Fig. 41).  
5. The role of Ctcf in the 3D structure of the IrxA cluster 
CTCF is an architectural protein (Ong and Corces 2014) that can bring together 
enhancers and promoters (Ribeiro de Almeida et al. 2011; Shih et al. 2012; Splinter et 
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al. 2006) and delimitate TADs (Dixon et al. 2012). Here, we show that the Irx cluster A 
has two interacting domains and the breakpoint of these domains has CTCF binding 
sites. Moreover, it was previously suggested that CTCF was implicated in the 3D 
structure of the loop formed by Irx1/Irx2 (Tena et al. 2011). Interestingly, upon Ctcf 
deletion, only the Irx4 gene presented a change in the 3D structure. The effect of this 
disruption was deregulation of genes from the cluster; Irx4 was downregulated and Irx1 
was upregulated. The neighboring genes telomeric from the cluster, Ndufs6, Mrlp36 
and Lpcat1, were also upregulated. Furthermore, the new interaction formed between 
the Irx4 promoter and a previously described neural enhancer that does not normally 
interact with this gene confirmed the disruption of the 3D structure of the cluster.  
Our results show that genomic 3D structure in the developing heart plays a role in gene 
regulation as its disruption impacts this process. Nevertheless, our results with a Ctcf 
KO model suggest that the general structure appears to be very stable and is not easily 
disrupted. Two possibilities can be put forward to explain this. 
The first possibility is that CTCF is not the only architectural protein involved in 
maintaining the 3D structure of the IrxA cluster or the genome in general, and in this 
setting other architectural proteins, such as cohesin, might be playing a role. Indeed, it 
has been previously shown that these two proteins can associate to promote long-
range interaction and hence 3D structure (Degner et al. 2011; Guo et al. 2012; 
Merkenschlager and Odom 2013; Nasmyth and Haering 2009; Zuin et al. 2014). 
Moreover, cohesin has been shown to alter 3D structure and gene expression at 
specific loci including Tcra, the IFNG locus, protocadherins and the reg locus 
(Cuadrado et al. 2015; Hadjur et al. 2009; Seitan et al. 2011). In the case of the Tcra 
locus, the 3D structure was both CTCF and cohesin dependent (Hadjur et al. 2009). 
Although CTCF and cohesin are most commonly associated with long-range 
interaction, additional architectural proteins such as mediator (Kagey et al. 2010; 
Phillips-Cremins et al. 2013) and YY1 (Atchison 2014), among others, might act more 
locally but still have a role in 3D structure.  
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Fig. 41. The 3D structure of the IrxA cluster. 
The IrxA cluster is divided into two subTADs. On top is a graphic representation of a Hi-C data 
from mouse ES cells (Dixon et al. 2012) where we can appreciate that the IrxA TAD seems to 
be divided in two subTADs. On the bottom the interaction profiles of the IrxA cluster genes and 
the first downstream gene from the Cluster A, Ndufs6, also show  the subdivision of the IrxA 
cluster. The centromeric subTAD contains Irx1 and Irx2. The telomeric subTAD contains Irx4.  
Two reports suggest that the general 3D structure is very stable. Depletion of cohesin 
in non-cycling CD4 cells leads to gene expression alteration but the global 3D structure 
is maintained (Seitan et al. 2013). As in our work, the impact of the loss of another 
architectural protein, cohesin, seems to be local rather than global. A second study in 
HEK293T cells showed that the absence of CTCF or cohesin did not disrupt TADs 
(Zuin et al. 2014). 
The second possibility is that indeed CTCF is necessary for the formation of the 3D 
structure of chromatin, but dispensable for its later maintenance. Hence, structures that 
change dynamically during development could be more susceptible to CTCF depletion; 
such would be the case for the recombination locus in B cells (Ribeiro de Almeida et al. 
2011), and promoter choice in the protocadherin alpha cluster (Hirayama et al. 2012). If 
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the second possibility is correct, we should expect changes in the 3D structure of 
cluster A in general. However, the iroquois genes have a dynamic expression pattern in 
other tissues including neural tissue and limbs. Conditional deletion of Ctcf in these 
contexts might answer this question. In our model, we deleted Ctcf in early heart 
development, before cardiac tissue specification but after mesoderm differentiation. 
Therefore, the chromatin very likely already has a 3D structure. Deletion of Ctcf at 
earlier stages in development could lead to embryonic lethality before cardiac 
specification is achieved. Thus, it is difficult to test if Ctcf is necessary for the formation 
of 3D structure in our working model.  
6. CTCF binding sites delimit the Irx4 regulatory landscape 
Given that Irx4 is in a different regulatory domain and is highly expressed in the heart, 
we hypothesized that its regulatory domain should harbor cardiac regulatory elements. 
Although the Irx4 interaction profile illustrates its interacting and hence regulatory 
domain, the precise limits were not entirely clear. However, the interactions 
centromeric to the gene seemed to decrease near CTCF binding sites. Moreover, a 
neural enhancer that did not show interaction with Irx4 under wild-type conditions 
(Tena et al. 2011) was upstream from the first CTCF binding site centromeric to Irx4. 
This site showed insulator activity in a zebrafish insulator assay (appendix E). Thus, we 
propose that this site is the upstream limit of the Irx4 regulatory domain.  
The downstream limit was less clear. The first decrease in interaction also occurred at 
a CTCF binding site telomeric to the gene and located proximal to Ndufs6. A different 
option for the Irx4 downstream limit lies further away and could terminate near the 
Lpcat1 promoter, for several reasons. First, the interaction map extends this far. 
Second, the promoter of Lpcat1 is in a genomic region that loses interaction with Irx4 
upon Ctcf depletion. Finally, this site harbors several CTCF binding sites that could act 
as boundaries. Since the upstream boundary is disrupted upon Ctcf deletion, this could 
also be a possibility for the downstream boundary. Further, as shown by our RNAseq 
analysis, the Irx4 downstream neighboring genes Ndufs6, Mrlp36 and Lpcat1 are 
expressed in the heart. Moreover, in situ hybridization showed that Ndufs6 and Mrlp36 
share Irx4 expression domains, and the 4C-seq profile of Irx4 and Ndufs6 
demonstrated that they share interacting regions. Taken together, these findings 
suggest that all four genes can share regulatory elements in the 350 kb region where 
they are located. Thus, the Lpcat1 promoter could be the Irx4 downstream regulatory 
landscape limit. 
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Previous work used DNA conservation to search for regulatory elements inside the IrxA 
cluster; however, none of the elements tested drove expression in the heart (Tena et 
al. 2011), raising the possibility that although conservation is useful to find regulatory 
elements, it may have to be complemented with other strategies (Blow et al. 2010; 
Visel et al. 2009). We followed the previously described strategy that uses histone 
marks to search for regulatory elements since histone modifications are associated 
with promoters, enhancers and active regions of DNA (H3K4me3, H3K4me1 and 
H3K27ac, respectively (Bernstein et al. 2006; Creyghton et al. 2010; Rada-Iglesias et 
al. 2011)). We aimed to uncover Irx4 regulatory elements and we searched for them in 
the 150 kb region flanked by CTCF binding sites. But, none of the enhancers tested 
recapitulated the whole Irx4 expression pattern. Nevertheless, 57% of the elements 
tested drove expression of the LacZ reporter gene in the heart. Thus, cardiac 
regulatory elements are indeed present in the region analyzed. We do not discard the 
possibility that enhancers that more precisely reproduce Irx4 expression exist in this 
150 kb region and that our strategy failed to find these elements. Clearly, alternative 
explanations for this lack of equivalency could be that those regulatory elements are 
located further away from the limited region we established, or that the combination of 
the enhancers identified is necessary to reproduce the full Irx4 expression pattern,. 
7. Looping Irx4 
Previous studies have shown that interaction between CTCF binding sites and 
promoters is necessary for gene expression (Ribeiro de Almeida et al. 2011; Shih et al. 
2012). Our results suggest that the Irx4 promoter interacts with CTCF binding sites 
upstream and downstream of the gene and that these interactions, besides delimiting 
the regulatory landscape, could be related to Irx4 regulation because when Irx4 is 
downregulated, there is also a decrease in interaction between the promoter and these 
CTCF binding sites. Our results suggest that the CTCF upstream site was a boundary 
for the Irx4 regulatory landscape. The interacting profile using this CTCF binding site as 
the viewpoint showed that it contacted the Irx4 promoter and other CTCF binding sites 
located downstream of Irx4. Although not statistically significant, these interactions 
were lost upon Ctcf deletion. Thus, this binding site interacts with the Irx4 promoter and 
very likely this interaction regulates Irx4 gene expression. The interacting profile from a 
close-by enhancer showed that it contacted the Irx4 promoter and that this interaction 
was also lost upon Ctcf deletion. Collectively, these findings strongly indicate that the 
3D structure of the Irx4 locus is CTCF dependent.  
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Finally, we deleted the CTCF binding site that we defined as the upstream limit of Irx4 
regulatory landscape. We did this using the CRIPSR/Cas9 system in transient 
transgenic assays. Interestingly, the deletion of this binding site downregulated Irx4 
expression only in the heart. This result has several implications. First, this CTCF 
binding site is directly associated with Irx4 expression and positively regulates this 
gene. This site loops towards the Irx4 promoter and in doing so likely brings regulatory 
elements to the gene. If this is the case, it provides an explanation for the 
downregulation of Irx4 when Ctcf or the CTCF-binding site is deleted. This site is 
located near the point that separates the two interacting regions of cluster A and is 
therefore an attractive candidate for a boundary element inside the cluster. Moreover, it 
could also be acting as an insulator since it separates genes with divergent expression 
patterns. If this site represented an actual insulator, we would expect a “contamination” 
of the regulatory domains inside the cluster A, and thus ectopic expression of Irx4. This 
ectopic expression would be expected in the expression territories of Irx1 and Irx2, 
which include the nervous system and limbs. However, Irx4 was not ectopically 
expressed in any edited embryo analyzed, indicating that it does not function as an 
insulator. Although the transient transgenic embryos were mosaic, they did not have 
the CTCF binding deletion restricted to the heart or any other tissue. It is conceivable 
that the looping from the genomic region close to the location of this CTCF binding site 
towards both sides of the cluster is actually what separates the regulatory domains. For 
example, the neural enhancer upstream of this site interacts with Irx1 and Irx2 
promoters (Tena et al. 2011) and the CTCF binding site (the one deleted) interacts with 
the Irx4 promoter. Both loops are established to regulate gene expression; they bring 
together regulatory elements and target promoters and, at the same time, restrict 
interaction between Irx1/Irx2 and Irx4 promoters. Our data allow us to propose that the 
Irx4 3D structure is CTCF mediated, and that this genomic region forms at least two 
loops with the CTCF binding sites upstream and downstream from the gene. In doing 
so, this 3D structure regulates Irx4 gene expression in the developing mammalian 
heart (Fig. 42).  
Using the IrxA cluster as an example, we show that 3D genomic structure is implicated 
in gene regulation and that CTCF is one of the players mediating 3D genomic structure 
during heart development.  
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Fig. 42. CTCF mediates Irx4 3D structure. 
The 3D structure of the IrxA cluster is depicted in the diagram on the left. Blueish circles 
represent CTCF and rectangles are the enhancers tested so far either in this work (red) or in 
previous works (yellow) (Tena et al. 2011). The diagram on the right depicts the 3D structure 
upon Ctcf deletion (represented by the absence of blueish circles). The loop containing Irx1 and 
Irx2 remains stable, whereas the 3D structure for proper Irx4 expression is dismantled. Irx4 
loses interaction with the Lpcat1 promoter and at the same time gains interaction with a neural 
enhancer (yellow rectangle next to Irx4).  
In this work, we show that the architectural protein CTCF helps to activate the cardiac 
transcription program in the developing heart. It does so by facilitating enhancer-
promoter interaction. Although CTCF can act as an insulator, it seems that other 
elements and mechanisms can separate regulatory domains, as in the case of Tbx and 
troponin genes. Our work also highlights that genes with divergent gene expression 
patterns very likely belong to different regulatory domains; such is the case for the 
cluster A iroquois genes. Moreover, we found that the global scaffolding of the 
chromatin is resilient to dismantling. However, there are regulatory landscapes 
susceptible to disassembly upon Ctcf loss. In conclusion the 3D structure is relevant 
and necessary for gene regulation in the developing mammalian heart. How CTCF 
reaches tissue specificity remains an open and intriguing question. Future work will 
help to find CTCF tissue specific partners and whether they help CTFC to stablish 3D 
structure for proper development and homeostasis maintenance. 
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1. Ctcf is necessary for heart development and its deletion in the mouse embryonic 
heart is embryonic lethal. 
2. Deletion of Ctcf in the developing heart causes severe cardiac malformations that 
include shortening of the interventricular septum and reduced thickness of the compact 
myocardial wall. 
3. Before cardiac malformations arise, deletion of Ctcf in the mouse embryonic heart 
does not alter cell proliferation or apoptosis. 
4. Ctcf is necessary for the activation of the cardiac developmental transcriptional 
program and it possibly does so by bringing together heart enhancers and target 
genes. 
5. The CTCF binding sites located between genes with divergent expression patterns 
do not always act as insulators in their genomic context. 
6. The IrxA cluster is divided into two regulatory landscapes of unequal size. The 
centromeric regulatory domain includes Irx1 and Irx2, and the telomeric domain 
includes Irx4. 
7. Loss of Ctcf in the mouse embryonic heart disrupts the 3D structure of the IrxA gene 
Cluster, and this alters gene expression of the IrxA cluster and neighboring genes. 
8. The regulatory landscape of Irx4 is delimited by CTCF binding sites and this 
genomic region contains regulatory elements that drive expression into the mouse 
embryonic heart. 
9. A specific CTCF binding site located between Irx2 and Irx4 is involved in establishing 
the proper 3D structure of the Irx4 regulatory landscape and is necessary for its correct 
expression. 
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1. Ctcf es necesario para el desarrollo cardiaco y su deleción en el corazón 
embrionario de ratón causa letalidad embrionaria. 
2. La deleción de Ctcf en el corazón en desarrollo causa malformaciones cardiacas 
severas, que incluyen un acortamiento del septo interventricular y una reducción en el 
grosor de la pared del miocardio compacto. 
3. Antes de que se detecten las malformaciones cardiacas, la deleción de Ctcf en el 
corazón embrionario de ratón no altera la proliferación celular ni la apoptosis. 
4. Ctcf es necesario para la activación del programa transcripcional de desarrollo 
cardiaco, y es posible que realice esta función al aproximar enhancers de corazón con 
sus genes blanco. 
5. Los sitios de unión a CTCF localizados entre genes con patrones de expresión 
divergentes no siempre actúan como aisladores en su contexto genómico. 
6. El cluster IrxA está dividido en dos regiones regulatorias de distinto tamaño. El 
dominio regulatorio centromérico incluye Irx1 e Irx2, y el dominio telomérico incluye 
Irx4. 
7. La pérdida de Ctcf en el corazón embrionario de ratón deshace la estructura 3D de 
los genes del cluster IrxA, y esto altera la expresión génica del cluster IrxA y de genes 
vecinos. 
8. La región regulatoria de Irx4 está delimitada por sitios de unión a CTCF, y esta 
región genómica contiene elementos reguladores que dirigen la expresión al corazón 
embrionario de ratón. 
9. Un sitio específico de unión a CTCF localizado entre Irx2 e Irx4 está involucrado en 
establecer la estructura 3D apropiada de la región regulatoria de Irx4, y es necesario 
para que se exprese correctamente. 
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Appendix A 
Paraffin sections RNA in situ pre-hybridization buffer 
Reagent Final concentration Reference 
Formamida 50% Fluka 47670 
SSC pH 5,5 20x 5x  
Denhardt´s 100x 2x  
Tween 20 0,1% Sigma P1379 
Chaps  0,1% Sigma C5070-5G 
tRNA 0,05mg/mL Sigma C5070 
Diluted in H2O RNAse free  
 
SSC 20x 
Reagent Final concentration Reference 
NaCl 150mM Merck  1064041000 
Sodium citrate dihydrate 15mM Sigma  C8532 
Diluted in H2O  
 
Denhardt´s 100x 
Reagent Final concentration Reference 
Ficoll 0,02 gr/mL Sigma F2637 
polyvinylpyrrolidone 0,02 gr/mL Sigma P5288 
BSA 0,02 gr/mL Sigma A7906 
Dilute in H2O RNAse free  
 
Paraffin sections RNA in situ Post-hybridization I buffer 
Reagent Final concentration Reference 
Formamida 50%  
SSC pH 5,5 20x 5x  
SDS 1% Biorad 161-0418 
Diluted in H2O RNAse free  
 
Paraffin sections RNA in situ Post-hybridization II buffer 
Reagent Final concentration Reference 
Formamida 50%  
SSC pH 5,5 20x 2x  
SDS 0,2% Biorad 161-0418 
Diluted in H2O RNAse free  
 
Paraffin sections RNA in situ Maleic buffer (MABT) 
Reagent Final concentration 
MABT 5X 1X 
Diluted in H2O RNAse free 
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Paraffin sections RNA in situ MABT 5X 
Reagent Final concentration Reference 
Maleic Acid 58,05 gr/L Sigma M0375 
NaCl 43,83 gr/L Merck 1.06404.1000 
Tween 20 0,5%  
Dilute in  H2O RNAse free  
Autoclave 
Paraffin sections RNA in situ Blocking solution 
Reagent Final concentration Reference 
Goat serum  Thermofisher C8532 
Blocking reagent 10% 1%  
Dilute in MABT 1X  
 
Blocking reagent 10% p/v  
Reagent Final concentration Reference 
Blocking reagent 10% (100g in 1L) Roche 11096176001 
Dilute in MABT 1X  
 
Paraffin sections RNA in situ AP-Buffer 
Reagent Final concentration Reference 
NaCl 0,1 M  
MgCl2 0,05M Sigma 63072 
Tris HCl pH 9,5 0,1 M Sigma  T3253 
Tween 20 0,1% Sigma  P9416 
Dilute in H2O RNAse free  
For embryos from E11.5 add Levamisol (Sigma L9756) at final concentration 2mM 
Whole mount RNA in situ pre-hybridization buffer 
Reagent Final concentration Reference 
Formamida 50%  
SSC 20x pH 4,5 4x  
tRNA  0,1 gr/mL  
SDS 20% 1%  
Heparin 0.05 gr/mL  
Blocking reagent 1%  
Dilute in  H2O RNAse free  
 
Whole mount RNA in situ Post-hybridization I buffer 
Reagent Final concentration Reference 
Formamida 50%  
SSC pH 4,5 20x 5x  
SDS 1% Biorad 161-0418 
Diluted in H2O RNAse free  
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Whole mount RNA in situ Post-hybridization II buffer 
Reagent Final concentration Reference 
Formamida 50%  
SSC pH 4,5 20x 2x  
SDS 0,1% Biorad 161-0418 
Diluted in H2O RNAse free  
 
Whole mount RNA in situ NTMT Buffer 
Reagent Final concentration Reference 
TrisHCl pH 9,5 0,125 M  
NaCl 0,125 M  
MgCl2 0,0625 M  
Triton X-100 25% 0,125% Sigma T9284 
Levamisol 1M 2,5 mM  
Dilute in H2O RNAse free  
 
TdT buffer 5x 
Reagent Final concentration Reference 
TrisHCl 0.125mM  
Sodium cacodylate 
trihydrate  
0.214gr/mL Sigma C4945 
BSA 0.0012 gr/mL Sigma A7906 
pH 6,6  
Diluted in H2O  
 
TdT buffer 1x 
Reagent Final concentration Reference 
Tdt 5x 1x  
CoCl2 1mM Sigma 255599 
Diluted in PBS1x  
Prepare at moment of use 
Histoblock 
Reagent Final concentration Reference 
BSA 0.03gr/mL  
MgCl2 0.02mM  
Tween 20 3% Merck 8170721000 
Goat serum   
Diluted in  PBS1X  
 
Microinjection Buffer 
Reagent Final concentration 
Tris HCl pH 7,4 50 mM 
EDTA 1 mM 
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Dilute in Oocyte water 
Store at -20ºC 
4Cseq Buffer 
Reagent Final concentration Reference 
TrisHCl pH 7,5 50 mM   
NaCl 150 mM  
EDTA 5 mM  
NP-40 (Igepal) 0,5 % Sigma 13021-100mL 
Tritón-100 20% 1%  
Protease inhibitor 1x Roche 11245200 
Diluted in PBS1x  
 
Appendix B 
Number of lived embryos recovered at different stages. 
 
Appendix C 
RNAseq data in an excel file in the CD 
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Appendix D 
Table 16. GO terms enriched in all DEG in controls versus Ctcf KO comparison 
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Table 17. GO terms enriched in downregulated DEG in controls versus Ctcf KO 
comparison 
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Table 18. GO terms enriched in upegulated DEG in controls versus Ctcf KO 
comparison 
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Table 19. GO terms enriched in all DEG in heterozygote versus Ctcf KO 
comparison 
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Table 20. GO terms enriched in downregulated DEG in heterozygote versus Ctcf 
KO comparison 
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Table 21. GO terms enriched in upegulated DEG in controls versus Ctcf KO 
comparison, part I 
  
APPENDIXES
 
161 
 
Table 22. GO terms enriched in upegulated DEG in controls versus Ctcf KO 
comparison, part II 
 
 
 
Appendix E 
Manuscript of this work in its current version and published article as a result of a 
collaboration are included in the CD. 
 
 
 
 
 
 
